Condensed Interim Consolidated Financial Statements

For the Three and Nine Months Ended December 31, 2020 and 2019 (Unaudited - In Canadian Dollars)

Notice of Disclosure of Non-auditor Review of the Condensed Interim Consolidated Financial Statements for the three and nine months ended December 31, 2020 and 2019.

Pursuant to National Instrument 51-102, Part 4, subsection 4.3(3)(a) issued by the Canadian Securities administrators, if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim consolidated financial statements of Australis Capital Inc. ("the Company") for the interim period ended December 31, 2020 and 2019, have been prepared in accordance with the International Accounting Standard 34 - *Interim Financial Reporting* as issued by the International Accounting Standards Board and are the responsibility of the Company's management.

The Company's independent auditors, Baker Tilly, have not performed a review of these condensed interim consolidated financial statements.

Condensed Interim Consolidated Statements of Financial Position

(Unaudited - in Canadian Dollars)

Notes	December 31, 2020	March 31, 2020
	\$	\$
	5 595 331	7 (4(010
2	7,585,221	7,646,919
	-	8,685,581
4,23	· · · · · · · · · · · · · · · · · · ·	380,655
	-	-
		332,324
		956,705
	66,070	53,081
	-	1,553,055
	-	38,396
	-	382,000
		2,977,532
9		709,350
	16,423,381	23,715,598
15(a)	500 678	500,678
	500,078	796,163
	0 354 205	790,103
• • • •	9,354,295	-
	-	10,500,148
		4,931,023
	7,225,815	14,775,466
,	-	589,843
	-),	739,067
		6,407,851
25		744,502
	41,004,581	63,700,339
	4 684 384	2,585,278
		2,505,270
25		141,563
	4,015,855	855,423
8		293,208
	9,403,341	3,875,472
0	1 200 037	1,448,493
		610,350
25	/	5,934,315
	1 1	
19	77,083,248	74,650,429
8,19	(101,456)	-
5,19	8,847,464	10,264,001
	228,845	527,974
	(56,226,374)	(27,676,380
	29,831,727	57,766,024
	$ \begin{array}{r} 3\\ 4,23\\ 6\\ 16\\ 16\\ 8\\ 7,10,17\\ 9\\ 15(a)\\ 15(b)\\ 15(c)\\ 16\\ 10,17\\ 18\\ 11,18\\ 6\\ 14\\ 25\\ 9,12,14(a)\\ 8\\ 9\\ 25\\ 19\\ 8,19\\ 19\\ 8,19\\ 10\\ 10\\ 10\\ 10\\ 10\\ 10\\ 10\\ 10\\ 10\\ 10$	$\begin{array}{c c c c c c c c c c c c c c c c c c c $

Nature of Operations (Note 1) Commitments and Contingencies (Note 25) Subsequent Events (Note 26)

Approved on March 1, 2021

Condensed Interim Consolidated Statements of Comprehensive Loss (Unaudited - in Canadian Dollars, except share amounts)

		Thre	e months ended	Nin	e months ended
			December 31,		December 31,
	Notes	2020	2019	2020	2019
Income		\$	\$	\$	\$
Income-Services		8,430	2,014	43,102	14,069
Income-Kiosks		35,181	-	71,510	-
Income-Consulting		46,767	47,765	143,368	155,065
		90,378	49,779	257,980	169,134
Cost of goods sold		(256,426)	-	(484,534)	-
Gross (loss) profit		(166,048)	49,779	(226,554)	169,134
Operating expenses		2 451 (15	1 020 025	E 00E 110	2 407 2 60
Wages and benefits	10() 10(0	3,451,617	1,238,825	5,097,118	3,407,260
Share-based payments	19(e),19(f)	(1,263,126)	957,129	391,507	4,210,958
Selling general and administrative	20	2,557,961	807,733	4,137,737	3,006,189
Depreciation and amortization	17,18,25	<u>152,341</u> 4,898,793	167,040 3.170,727	496,355 10,122,717	433,312 11,057,719
		4,070,175	5,170,727	10,122,717	11,057,717
Loss from operations		(5,064,841)	(3,120,948)	(10,349,271)	(10,888,585)
Other income (expense)					
Gain (loss) on asset disposal		82	(2,016)	138	(3,824)
Impairment loss – SubTerra annuity receivable		-	-		(282,389)
(Loss) gain on investment in associate	16	(427,739)	1,122,162	(1,282,451)	(517,252)
Loss on settlements	9,13	(3,000,000)	-	(4,025,477)	-
Loss on true-up provision	14(a)	-	-	(1,615,835)	-
Loss on impairment of intangible assets	18	(7,684,824)	-	(7,684,824)	-
Loss on remeasurement of land held for sale	7	(2,250,241)	-	(2,250,241)	-
Recognition on deferred gain Net change on investment at fair value through		-	266,200	-	2,282,141
profit or loss	15	(796,163)	(3,060,507)	(992,718)	(3,203,608)
Other income		70	175	483	220,860
Other expense – M&A		(118,311)	(935,924)	(286,846)	(935,924)
Foreign exchange loss		(88,989)	(115,648)	(87,192)	(167,760)
Interest and other expenses		(12,712)	(50,919)	(23,195)	(93,104)
Interest expense – Leases		(4,880)	(18,683)	(38,685)	(58,981)
Interest income		26,460	86,710	86,120	863,765
		(14,357,247)	(2,708,450)	(18,200,723)	(1,896,076)
Net loss for the period		(19,422,088)	(5,829,398)	(28,549,994)	(12,784,661)
Other comprehensive income (loss)					
Other comprehensive income (loss) Foreign currency translation		6,010	20,846	(247,153)	(160,481)
Share of OCI from investments in associates		144,441	43,850	(51,976)	132,115
Comprehensive loss for the period		(19,271,637)	(5,764,702)	(28,849,123)	(12,813,027)
Net loss per share					
Basic and diluted		(0.11)	(0.03)	(0.17)	(0.08)
Weighted average number of shares					
outstanding		187 814 200	1 (7 071 441	150 005 050	150.050 450
Basic and diluted		176,512,309	167,871,441	172,937,978	159,852,460

Condensed Interim Consolidated Statements of Changes in Equity (Unaudited - in Canadian Dollars, except share amounts)

	Notes	Common shares	Share capital	Treasury shares	Share-based reserves	Warrant reserves	Accumulated other comprehensive income	Accumulated deficit	Total equity
		#	\$	\$	\$	\$	\$	\$	\$
Balance, March 31, 2019		145,062,954	56,305,201	-	268,372	8,105,364	329,618	(4,334,232)	60,674,323
Shares issued for acquisition of Green Therapeutics, LLC	9								
assets	9	7,831,855	8,615,041	-	-	-	-	-	8,615,041
Shares issued for acquisition of land	10	3,585,521	3,944,073	-	-	-	-	-	3,944,073
Finders fees	9	109,090	119,999	-	-	-	-	-	119,999
Shares issued for acquisition of Intangible Asset Passport									
License		1,829,219	1,058,626	-	-	-	-	-	1,058,626
Exercise of warrants	19(d)	9,999,838	2,988,162	-	-	(488,202)	-	-	2,499,960
Warrant forfeitures	19(d)	-	249,130	-	-	(249,130)	-	-	-
Exercise of stock options, net of withholding	19(e)	876,686	20,520	-	(121,133)	-	-	-	(100,613)
Vesting of RSU's, net of withholding	19(f) 19(e),	614,167	-	-	-	-	-	-	-
Share-based payments	19(f)	-	2,203,602	-	2,007,355	-	-	-	4,210,957
Prior period adjustments		-	-	-	-	-	-	(429,903)	(429,903)
Net loss for the period		-	-	-	-	-	-	(12,784,661)	(12,784,661)
Other comprehensive loss for the period		-	-	-	-	-	(28,367)	-	(28,367)
Balance, December 31, 2019		169,909,330	75,504,354	-	2,154,594	7,368,032	301,251	(17,548,796)	67,779,435

	Notes	Common shares	Share capital	Treasury shares	Share-based reserves	Warrant reserves	Accumulated other comprehensive income	Accumulated deficit	Total equity
Balance, March 31, 2020		169,943,997	74,650,429	-	2,895,969	7,368,032	527,974	(27,676,380)	57,766,024
Shares issued for acquisition of Paytron, LLC assets	11, 19(b)	949,926	170,717	-	-	-	-	-	170,717
Return of shares relating to the disposal of Mr. Natural assets	8, 19(c)	(533,981)	-	(101,456)	-	-	-	-	(101,456)
Shares issued pursuant to the agreements with Passport Technology Inc. and the Company's former CEO	13, 19(b)	4,250,000	595,000	-	-	-	-	-	595,000
Vesting of RSUs, net of withholding Share-based payments, net of forfeitures and	19(f) 19(e),	2,148,509	(149,681)	-	-	-	-	-	(149,681)
cancellations	19(c), 19(f)	-	1,493,735	-	(1,093,489)	-	-	-	400,246
Warrant forfeitures	19(d)	-	323,048	-	-	(323,048)	-	-	-
Net loss for the period		-	-	-	-	-	-	(28,549,994)	(28,549,994)
Other comprehensive loss for the period		-	-	-	-	-	(299,129)	-	(299,129)
Balance, December 31, 2020		176,758,451	77,083,248	(101,456)	1,802,480	7,044,984	228,845	(56,226,374)	29,831,727

Condensed Interim Consolidated Statements of Cash Flows

(Unaudited - in Canadian Dollars)

		Nine months ended D	
	Notes	<u>2020</u> \$	2019
Cash provided by (used in)		Φ	φ
Operating activities			
Net loss for the period		(28,549,994)	(12,784,661)
Adjustments to non-cash items			
Depreciation	17	85,784	67,752
Depreciation - leases	25	119,328	133,701
Interest income – leases		57,274	(13,849)
Amortization of intangibles	18	460,940	231,859
Share-based payments	19(e),19(f)	391,507	4,210,958
Gain on asset disposal			3,824
Impairment loss – SubTerra annuity receivable		-	282,389
Impairment loss - intangible assets		7,684,824	,
Loss on remeasurement of land held for sale	7	2,250,241	-
Loss on settlements	13	4,025,477	-
Loss on settlements Loss on true-up provision	14(a)	1,615,835	-
Loss on investment in associates	16	1,282,451	517,252
Recognition of deferred gain	10	1,202,431	(2,282,141)
Net change on investments at fair value through profit or		-	(2,202,141)
loss	16	992,718	3,203,608
Unrealized foreign currency loss	10	71,596	254,153
Changes in non-cash working capital		/1,590	254,155
Accounts receivable and others		185,401	04 204
		<i>2</i>	94,204
Prepaid expenses and deposits		548,688	(336,770)
Inventory		(778,893)	-
Accounts payable and accrued liabilities		1,407,817	1,303,019
Deferred revenue		8,276	-
Payment of royalty – Mr. Natural		-	(81,995)
Liabilities associated with assets held for sale – Mr. Natural		(12,664)	-
Net cash used in operating activities		(8,153,394)	(5,196,697)
Investing activities			
Purchase of interest in investment in associate	16	-	(6,396,920)
Proceeds from repayment of BaM loan	16	-	5,340,000
Purchase of property, plant and equipment	17	(1,166,622)	(661,972)
Acquisition of License Agreement with Passport			
Technology		-	(493,264)
Proceeds from sale of equipment		5,617	-
Proceeds from sale of investments in associates held for sale	16	469,978	-
Net cash used in investing activities		(691,027)	(2,212,156)
Financing activities			
Lease liability (principal)	25	(148,829)	(106,814
Exercise of warrants	19(d)	(=,, , -	2,502,156
Exercise of stock options	19(e)	-	180,000
Payment of tax withholdings upon settlement of options and	1)(0)		100,000
restricted stock unit awards		(149,681)	-
Net cash (used in) provided by financing activities		(298,510)	2,575,342
Effect of foreign exchange on cash and restricted cash		395,652	(212,513)
Decrease in cash and restricted cash		(8,747,279)	(5,046,024)
Cash and restricted cash, beginning of period		16,332,500	24,515,494
Cash and restricted cash, beginning of period		7,585,221	19,469,470
Cush and restricted cash, end or period		1,505,221	17,407,470
Supplementary information		40	
Cash paid for interest - leases		42,677	78,758
Cash received for interest		12,250	817,827
Cash received for dividends		-	24,675

1. Nature of Operations

Australis Capital Inc. (the "Company" or "ACI") was incorporated under the Business Corporations Act (Alberta).

The head office and principal address of the Company is 376 East Warm Springs Road, Suite 190, Las Vegas, Nevada, USA 89119. The Company's registered and records office address is Suite 1500 - 1055 West Georgia Street, Vancouver, BC V6E 4N7.

The Company filed a preliminary prospectus dated June 19, 2018 and filed a final prospectus dated August 14, 2018, for the spin-out of the Company by Aurora Cannabis Inc. ("ACB"), its former parent company. On August 16, 2018, the Company received a receipt for its final prospectus, and on September 19, 2018, ACB completed a distribution of the Company's shares and warrants. The Company's shares and warrants commenced trading on the Canadian Securities Exchange (the "CSE") on September 19, 2018 under the trading symbol "AUSA". On February 6, 2019, the Company's common shares commenced trading on the OTCQB® Venture Market under the ticker symbol "AUSAF."

On July 12, 2018, the Company incorporated Australis Capital (Nevada) Inc. ("ACN") in the State of Nevada. The Company held a 50% interest in Australis Holdings LLP ("AHL") prior to its spin-out from ACB, and on July 17, 2018, the Company, through ACN, acquired the remaining 50% interest in AHL from its joint venture partner, AJR Builders Group LLC ("AJR"), such that ACI owns 98.7% of AHL and ACN owns the remaining 1.3%. On November 2, 2018, the Company completed the acquisition of all of the issued and outstanding shares of Rthm Technologies Inc. ("Rthm"). On February 22, 2019, the Company formed Australis Perennial, LLC ("Perennial") in the State of Nevada. On May 15, 2019, the Company formed Australis Prosper") and Australis Terrain, LLC ("Terrain") in the State of Nevada. On November 8, 2019, the Company formed Cocoon Technology, LLC ("Cocoon") in the State of Nevada.

On November 17, 2020, the Company held its annual and special meeting of the shareholders (the "AGM"), at which the Company's shareholders voted on, among other topics, changes to the Company's Board of Directors. Two groups, one led by management and incumbent members of the Board of Directors of the Company, and the other, a group of concerned shareholders (the "Concerned Shareholders"), each published for shareholder review and consideration, information circulars outlining proposed future plans for the Company and a slate of Board of Director nominees. The outcome of the shareholder vote was significantly in favor of the proposals and nominees of the Concerned Shareholders. As a result of proxies received in favour of the Concerned Shareholders prior to the AGM, on the date of the AGM, the Company's incumbent Board of Directors agreed not to stand for re-election, resulting in the replacement of the Board in its entirety and the election of the nominees of the Concerned Shareholders being Dr. Duke Fu, Dr. Jason Dyck, Mr. Avi Geller, Mr. Hanoz Kapadia and Mr. John Esteireiro. Further, current management of the Company, including the Company's Chief Executive Officer, Chief Financial Officer, Chief Operating Officer and Chief Legal Officer, tendered their resignation as officers of the Company, with each choosing their respective resignations to be effective December 18, 2020. The newly composed Board elected to terminate the former executives for cause effective December 16, 2020 and to void the former executives' October 2020 employment agreements as breaches of their fiduciary duties. The Company's former Chief Executive Officer, Chief Operating Officer and Chief Legal Officer have initiated arbitration proceeding to recover severance. The newly elected directors of the Company appointed Dr. Duke Fu as Interim Chief Executive Officer. On December 30, 2020, the Company announced the appointment of Jon Paul as its new Chief Financial Officer effective January 1, 2021.

On January 5, 2021, the Company and 2750176 Ontario Inc. ("ALPS") announced that they, along with the holders of the outstanding shares of ALPS, entered into a non-binding term sheet setting forth the terms on which the Company is to acquire 51% of the issued and outstanding shares of ALPS, with an option to purchase the remaining 49%. As a condition to the completion of the proposed transaction, Terry Booth, currently a principal of ALPS, will become CEO of the Company at closing, taking over from Dr. Duke Fu, who has been serving as Interim CEO since November 17, 2020. At the time of closing the ALPS acquisition, Dr. Fu will take on the role of COO of the Company. On February 24, 2021 the Company announced it has reached a definitive agreement with ALPS and its shareholders on this acquisition and expects to close the acquisition in early March 2021.

2. Basis of Presentation and Significant Accounting Policies

(a) Basis of presentation

The unaudited condensed interim consolidated financial statements of Australis Capital, Inc. (the "Company") and its wholly owned subsidiaries have been prepared in accordance with International Accounting Standard 34, *Interim Financial Reporting*. The Company followed the same accounting policies and methods of computation as those disclosed in the annual audited consolidated financial statements for the year ended March 31, 2020, except as updated in Note 2(d) through Note 2(f) below. These unaudited condensed interim consolidated financial statements should be read in conjunction with the annual financial statements of the Company for the year ended March 31, 2020, which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations of the IFRS Interpretations Committee ("IFRIC").

During the three months ended September 30, 2020, the Company launched operations of Cocoon Technology. In connection with the launch of operations, the Company changed the presentation of its Condensed Interim Consolidated Statements of Comprehensive Loss, from a "nature of expense" method of classification to a "cost of sales" method of classification, such that expenses directly related to the revenue generating activities of the Company are presented as cost of sales, and separate from selling, general and administrative expenses. Presentation of the Company's Consolidated Statements of Comprehensive Loss using the cost of sales method, provides reliable and more relevant information about the effects of transactions and other events or conditions on the Company's financial performance and will continue such that comparability is not impaired in future periods. In accordance with IAS 1, *Presentation of Financial Statements*, the Company has also presented comparative amounts in the Condensed Interim Consolidated Statements of Comprehensive Loss, using the cost of sales method.

These condensed interim consolidated financial statements were approved and authorized for issue by the Board of Directors of the Company on March 1, 2021.

(b) Basis of consolidation

These condensed interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries (as described below) with intercompany balances and transactions eliminated on consolidation. Subsidiaries over which the Company has control are fully consolidated from the date control commences until the date control ceases. Control exists when the Company is exposed, or has rights, to variable returns from its involvement with the entity and can use its power to affect its returns. As of December 31, 2020, the Company has 100% control over the following entities, with the Company, as the parent entity:

Entity	Location	Functional Currency
Australis Capital Inc. (ACI)	Nevada (USA)	Canadian Dollar
Australis Capital (Nevada) Inc. (ACN)	Nevada (USA)	U.S. Dollar
Australis Holdings LLP (AHL)	Washington (USA)	U.S. Dollar
Rthm Technologies Inc.	Ontario (Canada)	Canadian Dollar
Australis Perennial LLC	Nevada (USA)	U.S. Dollar
Australis Prosper LLC	Nevada (USA)	U.S. Dollar
Australis Terrain LLC	Nevada (USA)	U.S. Dollar
Cocoon Technology LLC	Nevada (USA)	U.S. Dollar

(c) Functional and presentation of foreign currency

All amounts in the condensed interim consolidated financial statements are presented in Canadian dollars, unless otherwise noted. The functional currencies of the Company and its subsidiaries are noted in the above table (Note 2(b)).

(d) Inventory

Inventory is comprised of finished goods, namely self-service kiosks, and is stated at the lower of cost or net realizable value ("NRV"). The Company procures these kiosks from a third-party provider, and the cost of purchase from the provider, including applicable freight charges, is the cost assigned to the kiosks in inventory. NRV is determined as the estimated selling price in the ordinary course of business less the estimated costs necessary to make the sale. Cost of inventory will subsequently be recorded within the line item "cost of goods sold" in the consolidated statements of comprehensive loss, generally on a weighted average cost basis. During the three and nine months ended December 31, 2020, the Company recognized \$34,425 and \$69,973 of inventory expense to cost of goods sold (\$nil for the three and nine months ended December 31, 2019).

(e) Revenue recognition

The Company recognizes revenue in accordance with IFRS 15, *Revenue from contracts with customers*, measured based on the consideration to which the Company expects to be entitled in exchange for providing services to its customers. Under IFRS 15 the Company's accounting policy for revenue recognition is as follows: i) identify the contract with the customer; ii) identify the performance obligation(s) in the contract; iii) determine the transaction price; iv) allocate the transaction price to the performance obligation(s); and (v) recognize revenue when (or as) performance obligation(s) are satisfied.

Consulting Revenue

Consulting Revenue consists of consulting fees for services provided to Body and Mind, Inc ("BaM") (Note 16). This revenue arises from a contract in which consulting and advisory services are provided over time. Revenue from consulting service fees is recognized as services are provided, for a term ending on the date that is the earlier of (1) five years following November 2, 2018, and (2) the date the Company no longer holds 10% or more of the issued and outstanding common shares of BaM and is measured using an output method.

Cocoon Platform Revenue

The Company's Cocoon Platform (the "Platform") is a platform-as-a-service solution for cannabis dispensaries, comprised of both hardware and a hosted software solution, and offers among other features, the facilitation of minimal contact sales transactions by dispensary patrons on self-service kiosks at dispensary locations. Revenue derived from the Platform includes fees associated with the sale and installation of self-service kiosks, access to the Platform's hosted software solution ("Platform-as-a-Service" or "PaaS"), and ongoing maintenance.

The sale of self-service kiosks is a distinct performance obligation satisfied at a point in time. Revenue related to the sale of the kiosk is recognized when control of the kiosk transfers to the customer, or at time of delivery. In the normal course of business, the Company does not accept kiosk returns and therefore no provision for estimated returns is recorded.

Installation of the kiosk is a distinct performance obligation satisfied at a point in time. Revenue related to installation, is recognized upon successful completion of the installation services provided. Invoicing of these services generally occurs upon completion of the installation services.

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited) December 31, 2020 and 2019

The nature of the Company's promise with respect to PaaS, is to provide continuous access to the Platform's hosted software solution over the customer's contract term. The nature of the Company's promise to provide continuous access to the platform (a "stand-ready" obligation), is substantially the same regardless of whether the day to day activities performed through dispensary use of the platform differ. Under a stand-ready obligation, the evaluation of the nature of the performance obligation is focused on each time increment rather than the underlying activities. Therefore, the Company views PaaS to comprise a series of distinct days of service that are substantially the same and have the same pattern of transfer to the customer. For providing this service, the Company receives a fee based on a percent of the transaction total completed on the platform. Given the nature of the promise and the fact that the underlying fees are based on unknown transaction value to be completed on the Platform over the contract term, the total PaaS consideration is determined to be variable consideration. The Company has determined that the variable fee relates specifically to the Company's efforts to satisfy the performance obligation of providing daily access to the Platform, and that allocating the variable consideration entirely to the performance obligation is consistent with the allocation objective of IFRS 15. Further, the uncertainty related to the amount of consideration to which the Company is entitled is resolved on a daily basis as the entity satisfies its obligation to provide daily Platform access. Therefore, the Company allocates and recognizes PaaS revenues each day, based on the percentage fee earned for transactions that are completed on the Platform that day. Invoicing of these services is commensurate with performance and occurs on a monthly basis.

The nature of the Company's promise with respect to ongoing maintenance services is also a stand-ready obligation. The nature of the Company's promise is to stand-ready to provide maintenance and upgrade services on an as-needed and if and when available basis over the contract term, and is substantially the same regardless of whether the day to day maintenance activities differ. The Company views ongoing maintenance services to comprise a series of distinct days of services that are substantially the same and have the same pattern of transfer to the customer. Satisfaction of this performance obligation is measured based upon time elapsed and the Company recognizes revenue ratably over the contract term, as the Company's performance obligation to stand ready to provide maintenance services is satisfied. Invoicing of these services is commensurate with performance and occurs on a monthly basis.

The timing of revenue recognition, billings and cash collections for the above listed performance obligations results in billed receivables, accrued receivables, and customer deposits (contract liabilities), each a current asset or current liability on the Company's consolidated statements of financial position. Payment terms can vary by customer; however, amounts billed are typically payable within 30 to 90 days. The Company does not offer financing as part of its contracts with customers.

As of December 31, 2020, the Company does not have significant unsatisfied performance obligations for contracts expected to be long-term, or contracts for which we recognize revenue at an amount other than for which we have the right to invoice for goods or services delivered or performed.

Deferred contract costs

Contract costs are typically expensed as incurred. Contract costs are deferred if the costs are expected to be recoverable and if either of the following criteria is met:

- (i) The costs of obtaining the contract are incremental or explicitly chargeable to the customer;
- (ii) The fulfillment costs relate directly to the contract or an anticipated contract and generate or enhance the Company's resources that will be used in satisfying performance obligations in the future.
- (f) Segment information

The Company has two operating segments: Cannabis (ACI, AHL, ACN, Perennial, Terrain and Prosper) and Technology (Rthm, Cocoon). The cannabis segment involves expenditures for the acquisition of premium brand names and intellectual property and for the construction of a cultivation and manufacturing facility. Technology includes the assets, liabilities and results of operations related to the Company's Cocoon Platform.

The Company has identified its operating segments based on the financial information that is reviewed and used by executive management (collectively, the Chief Operating Decision Maker, or "CODM") in assessing performance and in determining the allocation of resources. The Company's CODM consists of the CEO and the CFO. The CODM considers the business from a single segment perspective and assesses the performance of the segment based on measures of profit and loss as well as assets and liabilities. Operations which generate no revenues and are incidental to the business activities will not be separate operating segments. Financial information about the operating segment is reviewed by the CODM on at least a quarterly basis.

(g) Significant accounting estimates and judgments

The preparation of financial statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. The significant judgments, estimates and assumptions made by management in preparing the unaudited condensed interim consolidated financial statements for the three and nine months ended December 31, 2020 and 2019 are consistent with those disclosed in the Company's annual audited consolidated financial statements for the year ended March 31, 2020.

(h) New or amended standards adopted

The following IFRS standards have been recently issued by the IASB and are applicable for financial reporting periods commencing on or after April 1, 2020. Pronouncements that are not applicable or not expected to have a significant impact to the Company have been excluded.

Amendments to IFRS 3, Business Combinations

IASB has issued on October 22, 2018 amendments to IFRS 3, which relate to the definition of a business. The amendments are as follows:

- Clarify that to be considered a business, an acquired set of activities and assets must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs;
- Remove the assessment of whether market participants are capable of replacing any missing inputs or processes and continuing to produce outputs;
- Add guidance and illustrative examples to help entities assess whether a substantive process has been acquired;
- Narrow the definitions of a business and of outputs by focusing on goods and services provided to customers and by removing the reference to an ability to reduce costs; and
- Add an optional concentration test that permits a simplified assessment of whether an acquired set of activities and assets is not a business.

The amendments are effective for business combinations for which the acquisition date is on or after the beginning of the first annual reporting period on or after January 1, 2020 and to asset acquisitions that occur on or after the beginning of that period. Early adoption of this amendment is permitted. The Company has adopted the amendment as of April 1, 2018.

The following is a brief summary of the new standards issued but not yet effective:

Amendments to IAS 1: Classification of Liabilities as Current or Non-Current

In January 2020, the IASB issued, *Classification of Liabilities as Current or Non-current ("Amendments to IAS 1")*, to clarify the requirements for classifying liabilities as current or non-current. The amendments affect only the presentation of liabilities in the statement of financial position, and not the amount or timing of recognition of any asset, liability, income or expense, or the information that entities disclose about those items. They clarify that the classification of liabilities as current or non-current should be based on rights that are in existence at the end of the reporting period; clarify that classification is unaffected by expectations about whether an entity will exercise its right to defer settlement of a liability; and make clear that settlement refers to the transfer to the counterparty of cash, equity instruments, other assets or services. The amendments are effective for annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The Company is in the process of determining the impact of the amendments on its financial results.

(i) Recast of comparative interim results

The Company recast certain comparative information in the condensed interim consolidated statements of comprehensive loss for the three and nine months ended December 31, 2019, to address certain measurement adjustments reflected in the Company's annual audited consolidated financial statements for the year-ended March 31, 2020. The adjustments are summarized as follows:

	Three months ended December 31, 2019	Nine months ended December 31, 2019
	\$	\$
Comprehensive loss as previously presented	(6,829,370)	(12,389,237)
Recasted items:		
Reduction in share-based payments	1,085,851	-
Impairment of Subterra	-	(282,389)
Impact on related items (interest, other)	(21,183)	(141,401)
Comprehensive loss recast	(5,764,702)	(12,813,027)

3. Cash and Restricted Cash

- (a) On September 17, 2018, the Company entered into an escrow agreement with its former transfer agent whereby the Company deposited into an interest-bearing account \$12,000,000 ("Restricted Funds") to be held and distributed upon written notice from the Company or in five years from the date of the escrow agreement. The terms of the escrow agreement include restrictions self-imposed by the Company, stating that in order for funds to be released from escrow, the Company must certify to the escrow agent that such funds are being used for investments made in accordance with the Company's investment policy. At the Company's Annual General Meeting held in September 2019, shareholders of the Company approved the lifting of these restrictions surrounding release of funds, with formal removal of the restrictions pending approval from the British Columbia Securities Commission (the "Commission"). On October 2, 2020, the Company was informed by the Commission, that due to the operational focus and efforts of the Company, the restrictions were no longer required. During the three months ended September 30, 2020, the funds were moved and reclassified from restricted cash to cash on the Company's condensed interim consolidated statements of financial position. During the three months ended December 31, 2020 the funds were transferred to an operating account and the restricted cash account was closed.
- (b) On October 25, 2018 and November 27, 2018, the Company completed a non-brokered private placement of 14,778,255 units and 1,084,451 units, respectively, at a price of \$2.03 per unit for aggregate gross proceeds of \$32,201,293 (net of a foreign exchange difference of \$9,964). The Company established an interest-bearing trust account with McMillan LLP and deposited the proceeds to be held and released upon written notice from the Company in accordance with the same terms outlined in Note 3(a). At December 31, 2020, \$nil was held in trust (\$289,662 as at March 31, 2020).

4. Accounts Receivable

Accounts receivable consists of the following:

	December 31,	March 31,
	2020	2020
	\$	\$
Trade accounts receivable	33,076	1,437
Interest receivable	53,958	90,483
Other receivables	42,222	288,735
	129,256	380,655

5. Spin-out Transaction

The Company filed a preliminary prospectus dated June 19, 2018 and filed a final prospectus dated August 14, 2018 with the securities regulatory authorities in each of the provinces and territories in Canada for the spin-out of the Company by ACB, and applied for its listing on the CSE (the "Spin-out Transaction"). On August 16, 2018, the Company received a receipt for its final prospectus and on September 19, 2018, ACB completed a distribution to holders of its common shares as of the record date of August 24, 2018, and as a return of capital, units of the Company, thereby effecting the Spin-out.

In connection with the Spin-out Transaction, on June 14, 2018, the Company entered into a Funding Agreement with ACB pursuant to which ACB advanced \$500,000 to the Company in consideration for which the Company provided ACB with the following share purchase warrants (the "Restricted Back-in Right"):

- (i) a warrant to purchase 20% of the issued and outstanding common shares of the Company as of the date on which its shares commence trading on the CSE, exercisable at a price of \$0.20 per share for a period of ten years from the date of issuance (22,628,751 warrants issued on September 19, 2018); and
- (ii) a warrant to purchase 20% of the issued and outstanding common shares of the Company as of the date of exercise of the Restricted Back-in Right, which will be exercisable for a period of ten years from the date of issuance at an exercise price equal to the five-day volume weighted average trading price of the Company's shares on the CSE or such other stock exchange on which the shares may then be listed at the time of exercise.

ACB is prohibited from exercising the Restricted Back-in Right unless all of the Company's business operations in the U.S. are legal under applicable federal and state laws and ACB has obtained the required consents of the TSX and other exchanges on which it may be listed at that time. The warrant described in (i) above meets the classification of an equity instrument and was initially recorded in reserves for the proceeds received of \$500,000. The warrant described in (ii) above meets the classification of a derivative liability instrument, however it is assigned a fair value of nil. Since the exercise price approximates the trading price, there is no value assigned to the warrant.

6. SubTerra Note Receivable

In connection with the Spin-out Transaction, the Company acquired certain assets ("SubTerra Assets") from Prairie Plant Systems Inc. ("PPS"), an indirect wholly-owned subsidiary of ACB, which consisted of:

- a 5% royalty on gross revenues of SubTerra earned annually from the sale of cannabis and cannabis-based products during the period commencing June 1, 2018 and ending May 31, 2028;
- an annual payment of \$150,000 from SubTerra during the period commencing June 1, 2018 and ending May 31, 2028; and
- a two-year option to purchase a parcel of land in Michigan, United States, for USD \$3,000 (the Company did not elect to purchase the land prior to expiration of the option).

SubTerra is a limited liability company organized under the laws of the State of Michigan. SubTerra operates a research facility located in White Pine, Michigan and has applied for a State of Michigan Class C Grower License and a State of Michigan Processor License for the production and processing of cannabis, respectively.

The SubTerra Assets recognized included the fair value of the annuity receivable of \$839,442 at time of acquisition. The fair value of the annuity receivable was determined using an annual payment of \$150,000 for ten years, discounted at a market rate of 12.24% applicable to SubTerra based on a rating of CCC or less. As at December 31, 2020, the short-term portion and long-term portion of the annuity receivable balances are \$66,070 and \$672,998, respectively (\$53,081 and \$739,067 as at March 31, 2020, respectively). Accretion for the three and nine months ended December 31, 2020 was \$22,730 and \$68,760, respectively (\$24,362 and \$74,379 for the three and nine months ended December 31, 2019, respectively) with an interest receivable balance related to SubTerra of \$52,871 as at December 31, 2020 (\$81,031 as at March 31, 2020).

SubTerra has made all payments due as of the date of filing of these financial statements. The Company anticipates full payment of the remaining annuity receivable and has recorded no provision for expected credit loss as of the period ended December 31, 2020.

7. AHL Land Held for Sale

AHL purchased two parcels of land in 2015 totaling approximately 24.5 acres (the "Property") in Whatcom County, Washington for \$3,033,010, with the initial intention to construct a new cannabis production and processing facility. The Company subsequently decided not to move forward with cannabis production on the acquired land and listed the land for sale as of the year-ended March 31, 2019.

Although circumstances have extended the period of time to sell beyond one year due to the COVID-19 pandemic, the Company continues to be committed to the sale of the land. The Company is working directly with potential buyers and expects to sell as of close of the current fiscal year. The fair value of the land is determined by a third-party appraiser, based on an as is market value of both parcels together, which is a Level 2 input. The land was remeasured based on management's best estimate of its fair value less estimated costs to sell following the discovery of wetlands not previously observed by the appraiser. During the three-month period ended December 31, 2020, the Company recognized a loss on remeasurement of the land held for sale of \$599,391. As at December 31, 2020, the land was carried at \$2,072,770 based on management best estimate of its fair value less estimated costs to sell (\$2,977,532 as at March 31, 2020). (Note 17). The land is a part of the Company's cannabis operating segment.

8. Acquisition of Mr. Natural Productions, Inc.

On February 26, 2019, the Company acquired 100% of Mr. Natural Productions, Inc. ("Mr. Natural"), a multiple awardwinning medical and recreational cannabis brand created in California. The acquisition included the rights to the Mr. Natural brand, the life story right of Robert Luciano and all related intellectual property, including proprietary processes (collectively, the "acquired assets"). Consideration provided, consisted of \$658,640 in cash and the issuance of 533,981 common shares in the capital of the Company valued at \$1.03 per share which was the fair value of the shares at the date of the transaction, as per the agreement.

As of March 31, 2020, management committed to the sale of the Mr. Natural Brand, Life Story and related intellectual property ("IP"). The Company classified the assets, and liabilities directly associated with the assets, namely future royalties payable, as held for sale as of the same period ended and remeasured the assets and liabilities to the lower of their carrying amount and fair value less costs to sell, bringing the carrying value of the asset held for sale to \$382,000 and the related liabilities to \$293,208. The asset is associated with the Company's cannabis operating segment.

On April 25, 2020, the Company entered into a Modification, Settlement, Assignment and Consent Agreement with Mr. Natural Productions, Inc. and Robert Luciano (collectively, the "Natural Parties"), and a third party (the "Assignee"). In connection with the agreement, the Company assigned and transferred all rights to the acquired assets, and any and all obligations arising from royalty payments based on future performance of the acquired assets, to the Assignee with the consent of the Natural Parties. In addition, the Natural Parties agreed to return to the Company the 533,981 common shares of the Company issued to the Natural Parties at time of acquisition. The shares were returned to the Company on April 30, 2020 at a value of \$101,456 based on the market price of the Company shares at close on the day prior to execution of the agreement, or \$0.19 per share (Note 19(c)). No gain or loss was recognized on disposal of the assets and related liabilities during the three or nine months ended December 31, 2020.

9. Asset Acquisition with Green Therapeutics, LLC

On May 21, 2019, the Company entered into an asset purchase agreement with Green Therapeutics, LLC ("GT") to acquire its Tsunami, Provisions, and GT Flowers cannabis brands, certain operating assets, intellectual property and the right to assume and complete the construction of a planned cultivation and production facility.

Consideration provided for the asset acquisition, consisted of 7,831,855 common shares of the Company valued at \$1.10 per share (based on the market price of the shares on May 17, 2019 as defined in the agreement). Additional consideration is to be provided upon completion of the following milestones:

- (i) USD \$800,000 in common shares will be issued when the new cultivation and production facility is fully licensed and operational; and
- (ii) USD \$800,000 in common shares will be issued if and when total operating income of USD \$800,000 is achieved before the start of the first harvest at the new production facility, after the facility is fully operational.

The Company also issued 109,090 common shares as a finder's fee related to the above acquisition.

Measurement

The Company accounted for the transaction as an asset acquisition. As the consideration provided was in the form of the Company's shares, in accordance with IFRS 2, the value of the equity issued is measured directly at the fair value of the assets received. The Company engaged an independent valuation firm to assess the fair value of the assets acquired and allocate the consideration provided based on their relative fair values. Valuations are highly dependent on the inputs used and assumptions made by management regarding the future performance of the assets acquired. To the extent possible, the Company utilized observable inputs, such as market prices for assets comparable to those acquired, however certain inputs and assumptions were based upon unobservable inputs, such as future revenue projections, and required significant judgment based on the best information available to management. Results of the independent valuation and allocation of consideration to assets acquired is outlined below.

The contingent consideration was measured on the date of acquisition at fair value of \$1,286,776 (\$956,000 USD), based on management's judgment of the probability and timing of when the milestones will be completed, considering factors such as the Company's degree of control over achievement of the milestone, activities undertaken at or around time of acquisition to progress achievement of the milestone and historical experience and results.

Total consideration for the assets acquired was \$8,711,008:

Consideration	\$
Common shares issued (inclusive of Finder's Fee)	7,424,232
Contingent consideration	1,286,776
Total Consideration Provided	8,711,008

The consideration provided is allocated to the assets acquired as follows:

Net Assets Acquired	\$
Other Current Assets - Working Capital	673,000
Production Equipment	200,370
Intangible Asset - Brands	3,799,638
Intangible Asset - Cultivation and Production Licenses	4,038,000
Total Consideration Provided	8,711,008

As of the period ended March 31, 2020, the Company reassessed the carrying amount of the contingent obligations to ensure that it reflects management's best estimate of the expected outflow required to settle the obligation as of the year then ended. During the year ended March 31, 2020, the Company recorded an increase to the contingent obligation of USD \$65,000 for a total contingent obligation of USD \$1,021,000 (\$1,448,493 CAD revalued using the period end spot rate) based on management's judgement of the updated probabilities and timing of when the milestones will be completed. Apart from a translation adjustment of the USD obligation to CAD of \$148,556 for a balance of \$1,299,937, no further adjustment was recorded to the contingent obligation during the nine months ended December 31, 2020.

On January 4, 2021, the Company entered into a non-binding term sheet with GT and the holders of the issued and outstanding membership interests of GT setting forth the terms of a proposed transaction pursuant to which Australis will purchase 100% of the issued and outstanding membership interests in GT. Prior to completing the acquisition, the parties have agreed to settle a previously announced legal dispute regarding the original May 2019 transaction. The transactions remain subject to a number of conditions including, without limitation, receipt of all applicable regulatory approvals.

During the three and nine months ended December 31, 2020, the Company recorded an estimated \$3,000,000 settlement and restructuring provision to address legal, restructuring, and other settlement obligations and costs which arose from events during the quarter, including costs incurred with the GT legal settlement and revised term sheet (Notes 25, and 26).

10. Land Acquisition with Meridian Companies, LLC

On May 20, 2019, the Company entered into an Agreement of Purchase and Sale with Meridian Companies, LLC ("Meridian"), and acquired from Meridian, an 8.9-acre parcel of land in North Las Vegas. This property has the potential to support a 400,000 square foot cultivation and production facility. Consideration, as determined by the fair market valuation of an independent appraiser, consisted of 3,585,521 common shares of the Company valued at \$1.10 per share (based on the market price of the shares on May 17, 2019 in accordance with the agreement).

Measurement

Acquisition of the land is recorded at cost. As the consideration provided was in the form of the Company's common shares, in accordance with IFRS 2, the value of the equity issued is measured directly, at the fair value of the assets received. The fair value of the land on the date of acquisition is determined by a third-party appraiser, based on an as-is market value of the parcel, or \$3,944,073.

On July 7, 2020, the Company entered into a non-binding letter of intent ("LOI") for the sale of its North Las Vegas land. The terms of the LOI are such that completion of the sale is subject to, among other customary closing conditions, execution of a formal purchase and sale agreement, completion of the Company's current contract for civil work land improvements on the North Las Vegas land, and a final investigation and review of the property.

On January 5, 2021, GT reached an agreement on the sale of land in North Las Vegas. In accordance with the settlement arrangement with Meridian, if the transaction is completed, AUSA will receive approximately USD \$1.95 million upon closing, subject to the satisfaction of the applicable closing conditions.

During the nine-month period ended December 31, 2020, the Company classified the land as held for sale. In addition, amounts carried as construction in progress ("CIP") and related to land improvements made to the North Las Vegas land, were also presented as held for sale as they will transfer to the buyer upon closing of the sale. During the three month period ended December 31, 2020, the Company recognized a loss on remeasurement of the land held for sale of \$1,650,850. As at December 31, 2020 the land was carried at \$4,370,000 based on management best estimate of its fair value less estimated costs to sell. (Note 17) The land and related CIP are part of the Company's cannabis operating segment.

11. Acquisition and disposal of Paytron, LLC

On April 1, 2020, the Company completed the acquisition of all of the equity interest of Paytron, LLC ("Paytron"), a merchant service provider and registered independent sales organization for certain payment processors. The acquisition includes all active merchant accounts of Paytron, established relationships with large payment processors, and the existing management and agent workforce of Paytron.

Consideration consisted of 949,926 common shares of the Company valued at \$0.18 per share based on the market price of the shares at the date of the transaction. Additionally, under the terms of the agreement, if Paytron achieves USD \$30,000 in net income for three consecutive months (the "Earnout Threshold"), on or before the 2nd anniversary of the transaction, the Company will issue up to USD \$1,000,000 in common shares of the Company. The contingent consideration was measured on the date of acquisition at a fair value of \$49,169 based on management's judgment as to the probability and timing of achievement of the Earnout Threshold. Total consideration for the acquisition was \$219,886.

Measurement

The transaction was determined to be a business combination under IFRS 3. The consideration paid for acquisition of the business has been allocated based on the Company's estimated fair value of the identifiable assets acquired as of the acquisition date. The customer relationships acquired have been assigned a useful life of seven years and will be amortized straight-line from the date of acquisition. The goodwill value arises from the assembled workforce and is not deductible for tax purposes.

Consideration	\$
Common Shares Issued	170,717
Contingent Consideration	49,169
Total Consideration Provided	219,886
Net Assets Acquired	\$
Customer Relationships	105,345
Goodwill	114,541
Total Consideration Provided	219,886

In September 2020, the Company entered into a series of connected agreements (collectively, the "Settlement Agreements") with Passport Technology, Inc. ("Passport Technology") and the Company's former CEO and Director, to fully and finally settle the termination of the Company's proposed acquisition of Passport Technology (Note 13). In connection with the Settlement Agreements, the Company transferred all operations, rights, previously acquired assets and related liabilities of Paytron, to Passport Technology, and reversed the provisions of the contingent obligation. This disposal is consistent with the Company's renewed focus on the United States Cannabis industry and commitment to focus efforts and resources on developing its United States cannabis operations. The Company recorded a loss on settlement of \$nil and \$164,315 during the three and nine months ended December 31, 2020 respectively.

Results of Paytron's operations for the period April 1, 2020 through date of disposition account for \$29,973 of the Company's total consolidated revenues and \$135,169 of the Company's total consolidated net loss.

12. License Agreement with Passport Technology Canada Ltd.

On October 29, 2019, the Company entered into a License, Development and Services Agreement with Passport Technology Canada Ltd. ("Passport"), to acquire an exclusive license to Passport's proprietary platform and technology for a term of 10 years (the "Passport License"). Passport is a developer of technology-based products and services for highly regulated payments, gaming and financial services markets. The Company will utilize the license right to customize the technology and develop a cloud-based, self-service fulfillment platform for use in cannabis dispensaries. At the conclusion of the contract term, the Company will own the customized technology. As consideration for the license right, the Company paid \$5,454,544 comprised of \$493,264 in cash, 5,000,000 shares of Body and Mind, Inc. ("Body and Mind" or "BaM") common stock, and 1,829,219 common shares of the Company.

The fair value of the BaM shares issued is based on a Level 1 input of a quoted market price in an active market but is discounted for certain restrictions placed on the trading of said shares. The discount applied to the quoted market price represents a Level 3 input and is managements' best estimate of the inherent risk associated with the requirement to hold the shares for a defined period of time. In accordance with IFRS 13, *Fair Value Measurement*, an entity shall not make an adjustment to a Level 1 input except when a quoted price in an active market does not represent fair value at the measurement date. It is the Company's position that the restrictions placed on the sale or trade of BaM shares following the Company's transfer of the shares to Passport, represent an increased risk to the acquiree when compared to the freely trading shares in the market, and as such, an adjustment to the quoted, market price best reflects the price that would be received to sell the asset in an orderly transaction between market participants at the measurement date. The Company assigned a fair value of \$3,902,654 to the BaM shares issued.

The fair value of the Company's shares is based on the Level 1 fair value input of the observed market price of the Company's shares as of the transaction date, \$0.58 per share, or \$1,058,626 for all shares issued.

The Company accounted for the license agreement as a finite life, intangible asset, and recorded the asset at cost based on the cash paid plus the fair value of the remaining consideration provided:

		Price per Share	\$
Consideration	Shares Issued	(CAD)	(CAD)
Cash	N/A	N/A	493,264
Body and Mind Common Shares	5,000,000	0.781	3,902,654
Australis Common Shares	1,829,219	0.579	1,058,626
Total Consideration Provided			5,454,544

The Company assigned a useful life of 10 years to the intangible asset and upon launch of the technology in connection with the Company's Cocoon Platform in September 2020, commenced straight-line amortization of the asset in the period then ended.

Additionally, under the terms of the agreement, the Company agreed to to reimburse Passport if as of June 13, 2020 (the "True Up Date"), the 30 day volume-weighted average share price of the BaM common shares on the CSE for the 30 trading days preceding the True Up Date (the "True Up Share Price") is less than 95% of the undiscounted share price at execution of the agreement. The Company agreed to make a one-time payment to Passport (the primary consideration of which is additional shares) in the amount up to the difference between the discounted share price at execution of the agreement and the True Up Share Price for 3,000,000 shares of BaM common stock. As of March 31, 2020, the Company recorded a provision and corresponding loss on acquisition of the Passport License in the amount of \$855,423, based on the above outlined true-up obligations of the agreement. On June 25, 2020, the Company transferred 1,802,542 common shares of BaM to Passport in settlement of the true-up obligation.

13. Termination of the proposed acquisition of Passport Technology, Inc. and the Settlement Agreements

On June 25, 2020, the Company entered into an agreement to acquire (the "Passport Acquisition") Passport Technology, Inc ("Passport Technology"), a developer of technology-based products and services for highly regulated payments, gaming and financial institutions. This arrangement falls within the scope of a related party transaction as the Company's former CEO and Director held the position of CEO and Director at the time this agreement was entered, and such individuals also had control over Passport Technology.

On August 2, 2020, the Company received a letter from Passport Technology purporting to assert a right to terminate the pending acquisition. The Company entered into a series of connected agreements on September 3, 2020 with Passport Technology and the Company's former CEO and Director, to formalize the termination and fully and finally settle all obligations and entitlements of the Company and Passport Technology with respect to the proposed acquisition (collectively, the "Settlement Agreements").

In addition, the following resulted:

- (i) The Company transferred all operations, rights, previously acquired assets and related liabilities of Paytron, LLC, to Passport Technology, and eliminated the earnout provisions payable to Paytron upon achievement of certain Earnout Thresholds, resulting in a loss of \$164,315 (Note 11).
- (ii) The Company amended the License, Development and Services Agreement with Passport Technology Canada, Ltd. (Note 12) such that the maintenance revenues generated from the Cocoon Platform self-service kiosks, previously to be shared between Passport Technology and the Company, would be retained solely by the Company and in exchange, the Company agreed to transfer and assign to Passport Technology, all rights, title and interest to fifteen of the Company's self-service kiosks valued at \$266,162.
- (iii) The Company entered into an agreement with the Company's former CEO and Director pursuant to which the former CEO and Director resigned from his then current position as Executive Chairman of the Board of Directors, and agreed to forgo all cash severance and surrender all previously granted stock options of the Company. The former CEO and Director retained all previously granted restricted share units, which fully vested upon resignation, and was issued 4,250,000 common shares of the Company with a fair value of \$595,000 based on a Level 1 input of the quoted market price of the shares at close of market on the day prior to settlement (Note 19).

14. Deposits

(a) Astound

On November 20, 2019, the Company entered into a three-year contract with Astound Group ("Astound"), a global marketing and creative firm, to provide brand optimization and awareness services for the Company's house of brands, including TsunamiTM, ProvisionTM, GT FlowersTM and CocoonRewardsTM, as well as for any new, future brands. As consideration, the Company transferred 5,000,000 shares of BaM to Astound, as an advance payment for the services to be provided.

The fair value of the BaM shares transferred to Astound is based on a Level 1 input of a quoted market price in an active market but is discounted for certain restrictions placed on the trading of said shares. The discount applied to the quoted market price represents a Level 3 input and is managements' best estimate of the inherent risk associated with the requirement to hold the shares for a defined period of time. In accordance with IFRS 13, *Fair Value Measurement*, an entity shall not make an adjustment to a Level 1 input except when a quoted price in an active market does not represent fair value at the measurement date. It is the Company's position that the restrictions placed on the sale or trade of BaM shares following the Company's transfer of the shares to Astound, represent an increased risk to the acquiree when compared to the freely trading shares in the market, and as such, an adjustment to the quoted, market price best reflects the price that would be received to sell the asset in an orderly transaction between market participants at the measurement date. The Company assigned a fair value of \$3,608,192 to the BaM shares issued.

The Company accounts for this transaction as a prepayment for future services. As services are rendered over the contract term, the Company will reduce the deposit balance in an amount equal to the value of the services provided based on Astound's standard billing rates, until the balance is depleted. If at conclusion of the three-year term, the value of services rendered is less than the value of the BaM shares transferred (or \$3,608,192), Astound will reimburse the Company for the difference in full.

Additionally, under the terms of the agreement, the Company agreed to reimburse Astound if on the first anniversary of the transaction (the "True Up Date"), the 30 day volume-weighted average share price of BaM shares on the CSE for the 30 trading days preceding the True Up Date (the "True Up Share Price") is less than the discounted share price (\$0.72 per share) at execution of the agreement. The Company agreed to make a one-time payment to Astound (in cash, the Company's shares or a combination of the two) in the amount up to the difference between the discounted share price and the True Up Share Price for each BaM share held by Astound as a result of this transaction, as of the True-up Date. As of December 31, 2020, the Company recorded a provision and corresponding loss on true-up obligation in the amount of \$1,615,835 based on the above outlined terms.

As of the period ended December 31, 2020, the Company has used a total of \$120,689 in services (of which, \$1,401 and \$67,424 were used during the three and nine months ended December 31, 2020 respectively) and the Astound deposit balance is \$3,487,503 (\$3,554,927 as of March 31, 2020).

On February 1, 2021, Astound served the Company with notice to make the true-up payment. The Company is in the process of negotiating a settlement with Astound.

(b) Rapid Cash

On December 14, 2019, the Company entered into a vendor agreement with RapidCash ATM Ltd. ("Rapid Cash"), a provider of ATM products and software solutions, for the purchase of retail kiosks to be used in conjunction with the Company's Cocoon Technology solution. As consideration, the Company transferred 5,000,000 shares of BaM to Rapid Cash, as an advance payment for kiosks to be procured in future periods.

The fair value of the BaM shares transferred is based on a Level 1 input of a quoted market price in an active market but is discounted for certain restrictions placed on the trading of said shares. The discount applied to the quoted market price represents a Level 3 input and is managements' best estimate of the inherent risk associated with the requirement to hold the shares for a defined period of time (the "Lock-up Period"). In accordance with IFRS 13, *Fair Value Measurement*, an entity shall not make an adjustment to a Level 1 input except when a quoted price in an active market does not represent fair value at the measurement date. It is the Company's position that the restrictions placed on the sale or trade of BaM shares following the Company's transfer of the shares to Rapid Cash, represent an increased risk to the acquiree when compared to the freely trading shares in the market, and as such, an adjustment to the quoted, market price best reflects the price that would be received to sell the asset in an orderly transaction between market participants at the measurement date. The Company assigned a fair value of \$2,749,178 to the BaM shares issued.

The Company accounts for this transaction as a prepayment for the procurement of retail kiosks in future periods. As the kiosks are procured, the Company will reduce the deposit balance in an amount equal to the value of the kiosks received, based on Rapid Cash's standard pricing, until the balance is depleted. During the Lock-up Period, the Company agreed to pay for the purchase of kiosks in cash. At completion of the Lock-up Period, the Company will begin depleting the prepaid balance. The Lock-up Period ended June 21, 2020.

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited) December 31, 2020 and 2019

Additionally, under the terms of the agreement, the Company agreed to reimburse Rapid Cash if eighteen months following contract execution (the "True Up Date"), the 30 day volume-weighted average share price of the BaM shares on the CSE for the 30 trading days preceding the True Up Date (the "True Up Share Price") is less than discounted share price (or \$0.55 per share) at execution of the agreement. The Company agreed to make a one-time payment to Rapid Cash (in cash, the Company's shares or a combination of the two) in the amount up to the difference between the discounted share price and the True Up Share Price for each BaM share held by Rapid Cash as a result of this transaction, as of the True-up Date. Further, if the proceeds received by Rapid Cash from the sale of BaM shares during the 6-month period between the end of the Lock-up Period and 12 months following contract execution, do not exceed the value of kiosks sold to the Company agreed to make a one-time, cash payment in the amount of the difference between the value of kiosks provided during the period and the proceeds from sale of BaM shares. Lastly, if Rapid Cash receives a profit from the sale of BaM shares during the 6-month period following the anniversary of execution of the contract and the True Up Date, Rapid Cash agreed to pay to the Company an amount equal to half of the profits received during the period.

In accordance with IAS 37, *Provisions, Contingent Liabilities and Contingent Assets*, these constitute possible obligations and a possible asset arising from prior events, the probability of which is based in part, on movement of BaM's share price and the activities of Rapid Cash with respect to the shares acquired, inputs not within the control of the Company. The Company treats these true ups as contingent obligations and a contingent asset and has therefore not recognized the obligations or asset as of the period ended December 31, 2020. The Company will assess the probability of the obligations and asset at each reporting period to determine if a provisional obligation or asset should be recorded.

As of the period ended December 31, 2020, the Company has used \$216,342 of deposit funds for the purchase of kiosks and the Rapid Cash deposit balance is \$2,532,836 (\$2,749,178 as of March 31, 2020).

On February 1, 2021 Rapid Cash served the Company with notice of termination of the agreement due to material breach and representation. On February 12, 2021, the Company responded, disputing those claims and rejected the unilateral termination of the agreement.

(c) Wagner Dimas

On February 26, 2020, the Company entered into an agreement with Wagner Dimas, Inc. whereby the Company returned to Wagner Dimas its holding of Wagner Dimas Class A shares. In connection with, and in exchange for the return of shares, the Company executed a Sales Order for the purchase of a Wagner Dimas pre-roll machine valued at \$464,835 (\$350,000 USD). The balance is carried in short-term deposits, pending receipt of the finished machine.

15. Marketable Securities

(a) Investment in Quality Green Inc.

On December 3, 2018, the Company entered into a subscription agreement with Quality Green Inc. ("Quality Green") to purchase units of the latter in connection with Quality Green's proposed going public transaction. Quality Green was incorporated under the jurisdiction of the Province of Ontario on July 16, 2013 and is domiciled in Canada. Quality Green is in the process of creating a business of growing, marketing, selling and distributing cannabis for medical and recreational uses. Pursuant to the terms of the subscription agreement, the Company acquired 3,636,364 units of Quality Green at a purchase price of \$0.55 per unit for total cash consideration of \$2,000,000. Each unit was comprised of one common share and one common share purchase warrant of Quality Green exercisable at \$1.00 per common share for a period of one year from the date of closing.

Measurement

The investment in Quality Green is accounted for at fair value through profit or loss. The Company is investing in a private Company where relevant observable inputs are not available. Transactions in such investments do not occur on a regular basis and are classified as Level 3. The fair value of the Company's investment in Quality Green as of March 31, 2019 was \$1,781,818 and \$145,455 for the common shares and the warrants, respectively.

The warrants procured under this investment were not exercised and expired on December 10, 2019. The Company therefore reversed the derivative asset as of December 31, 2019, resulting in the recognition of a loss in the amount of \$145,455 during the period then ended.

As relevant, observable inputs for Company's investment in the common shares of Quality Green are not available, the Company utilized available entity specific and market data to reassess the fair value of the Company's investment in the common shares of Quality Green as of March 31, 2020. Declines in the stock market for Canadian cannabis companies, as well as the delay in Quality Green's proposed going public transaction resulted in a loss on investment of \$1,281,140 and an overall investment fair value of \$500,678 as of March 31, 2020.

The Company is not aware of any significant changes in conditions of the business of Quality Green during the nine months ended December 31, 2020 and did not record an adjustment to fair value of the investment during the period then ended. Based on information available, management does not anticipate a further loss in the fair value of this investment as of December 31, 2020.

(b) Investment in Folium Equity Holding, LLC

On January 14, 2019, the Company entered into a subscription agreement with Folium Equity Holding, LLC ("Folium"), a vertically integrated producer, manufacturer, and distributor of hemp derived phytocannabinoids in the United States. The Company acquired the amount of \$3,988,200 (USD \$3,000,000) in Class A non-restricted membership interest at a price of USD \$1 per unit of membership interest. The cash represents the total consideration paid.

Measurement

The investment in Folium is accounted for at fair value through profit or loss. The Company is investing in a private company where relevant observable inputs are not available. Transactions in such investments do not occur on a regular basis and are classified as Level 3. The fair value of the investment as at fiscal year-ended March 31, 2019 was \$3,980,811.

Utilizing entity specific information as well as market factors, such as declining retail prices of CBD and the uncertainty surrounding the Food and Drug Administrations' ("FDA") involvement in the CBD space, the Company reassessed the fair value of the investment balance recorded as of March 31, 2020. The Company recognized a loss on investment of \$3,184,648 during the year ended March 31, 2020 resulting in an investment fair value of \$796,163 for the period then ended. During the nine months ended December 31, 2020, the Company determined that its investment is no longer recoverable given doubts over Folium's ability to carry on business as a going concern. Accordingly, the remaining carry value of \$796,163 was written down in the comprehensive statement of loss.

(c) Investment in Body and Mind.

On December 31, 2020, the Company determined that the criteria for significant influence and equity accounting of BaM, was no longer met, and both the BaM investment in associate (comprising 18,193,100 BaM shares at a fair value of \$8,823,910) and BaM assets held for sale (comprising 1,093,545 BaM shares at a fair value of \$530,385) were reclassified to marketable securities (see Note 16). As at December 31, 2020, the fair value of the 19,286,645 BaM shares was \$9,354,295 based on the market price of \$0.485 per BaM share.

16. Investment in Associates – Body and Mind, Inc.

On November 2, 2018, the Company completed an investment in BaM pursuant to an investment agreement dated October 30, 2018, and acquired a 25% ownership interest in BaM as follows:

- (a) 16,000,000 units of BaM at a price of \$0.40 per unit for gross proceeds of \$6,400,000. Each unit consisted of one common share and one share purchase warrant exercisable at a price of \$0.50 per share for a period of two years, subject to acceleration if the closing price of the common shares of BaM is equal to or greater than \$1.20 for 30 consecutive trading days; and
- (b) \$1,600,000 principal amount of 8% unsecured convertible debentures of BaM convertible at \$0.55 per share until November 2, 2020, subject to acceleration if the closing price of the common shares of BaM is equal to or greater than \$1.65 for 20 consecutive trading days.

In addition, under the terms of the investment agreement:

- (a) BaM entered into a commercial advisory agreement with the Company pursuant to which BaM agreed to pay the Company USD \$10,000 per month (as subsequently amended to USD \$12,000 per month beginning June 1, 2019) for advisory and consulting services for a term ending on the earlier of five years from the closing date, and the date the Company ceases to hold 10% of the issued and outstanding shares of BaM; and
- (b) for as long as the Company owns 10% of the issued and outstanding shares of BaM, the Company will be entitled to nominate one director to the board of BaM and one more director if the Company exercises all of the warrants and converts all of its debentures in BaM. The Company will be entitled to maintain two directors on the board of BaM if it maintains at least a 25% ownership interest in BaM. On November 2, 2018, the Company nominated one director to the board of BaM.

In accordance with IAS 28, *Investment in Associates and Joint Ventures*, if an entity holds, directly or indirectly, 20% or more of the voting power of the investee, it is presumed that the entity has significant influence, unless it can be clearly demonstrated that this is not the case. The Company concluded that the November 2, 2018 acquisition of the 25% ownership in BaM constitutes significant influence over the investee and as such, accounted for the purchase of voting-right share instruments under the equity method of accounting. Transactions involving the acquisition of derivative instruments, or other instruments that do not hold current voting rights, are accounted for under the appropriate IFRS guidance.

On November 28, 2018, the Company executed a loan agreement with BaM in which the Company advanced the principal amount of \$5,340,000 (USD \$4,000,000) to BaM at a rate of 15% per annum accruing and payable in arrears at the end of each six month period following the date of the agreement either in cash or in kind (the "Note"). BaM maintained prepayment rights at any time, in any amount, unless it is within the first year in which case BaM would be required to pay a 5% prepayment penalty on the amount repaid.

As of March 31, 2019, the Company acquired an additional 6,079,788 shares in BaM through exercise of 3,206,160 warrants acquired in connection with the October 30, 2018 investment agreement, through a finance fee of 1,105,083 shares issued in connection with a loan from the Company to Body and Mind issued in November 2018, and through acquisition of 1,768,545 shares on February 1, 2019.

On May 29, 2019, the Company acquired, through the exercise of its remaining 12,793,840 warrants of BaM, ownership of 12,793,840 common shares in the capital of BaM. The Company paid \$6,396,920 to exercise the warrants at a price of \$0.50 per share, and the warrants were carried at a fair value of \$6,524,858 at the time of exercise, for a total fair value as deemed cost of \$12,921,778 recorded to investment in associate. With the proceeds from warrant exercise, BaM repaid to the Company, the \$5,340,000 loan including interest incurred through the date of repayment of \$397,208 and a prepayment penalty of \$267,000.

December 31, 2020 and 2019

On October 29, 2019, the Company transferred to Passport Technology Canada, Ltd. ("Passport") 5,000,000 shares of BaM (Note 12), representing a 14.3% reduction in ownership held by the Company from 34,873,628 shares to 29,873,628 shares held. As a result of the transfer, the Company recorded a reduction to investment in associates in proportion to the reduction in ownership interest of the investee, or \$2,934,287 based on the carrying value of the investment at time of transfer. The Company recorded a gain on disposition of \$968,366 in the period ended December 31, 2019, representing the difference between the carrying value of the transferred interest and the consideration received in exchange for the transferred interest.

On November 20, 2019, the Company transferred to Astound, 5,000,000 shares of BaM (Note 14(a)), representing a further 16.7% reduction in ownership held by the Company from 29,873,628 shares to 24,873,628 shares held. As a result of the transfer, the Company recorded a reduction to investment in associates in proportion to the reduction in ownership interest of the investee, or \$2,920,498 based on the carrying value of the investment at time of transfer. The Company recorded a gain on disposition of \$687,694 in the period ended December 31, 2019, representing the difference between the carrying value of the transferred interest and the consideration received in exchange for the transferred interest.

On December 14, 2019, the Company transferred to Rapid Cash, 5,000,000 shares of BaM (Note 14(b)), representing a 20.1% reduction in ownership held by the Company from 24,873,628 shares to 19,873,628 shares held. As a result of the transfer, the Company recorded a reduction to investment in associates in proportion to the reduction in ownership interest of the investee, or \$2,904,091 based on the carrying value of the investment at time of transfer. The Company recorded a loss on disposition of \$154,913 in the period ended December 31, 2019, representing the difference between the carrying value of the transferred interest and the consideration received in exchange for the transferred interest.

On June 25, 2020, the Company transferred an additional 1,802,542 shares of BaM to Passport in settlement of the Company's provision payable to Passport in connection with the true-up conditions of the License, Development and Services Agreement (Note 12). The transfer resulted in a reduction in ownership held by the Company of 10.6% from 17,086,551 shares to 15,284,009 shares held. As a result of the transfer, the Company recorded a reduction to investment in associates in proportion to the reduction in ownership interest of the investee, or \$972,401 based on the carrying value of the investment at time of transfer. The Company recorded a loss on disposition of \$116,978 in the period ended June 30, 2020, representing the difference between the carrying value of the transferred interest and the obligation settled in exchange for the transferred interest.

BaM shares Held for Sale

On February 18, 2020, the Company transferred to a brokerage account, 1,018,532 shares of BaM for immediate sale. The Company classifies the shares transferred to the brokerage account as held for sale as of the date of transfer and measures the shares at the lower of their carrying amount and fair value less costs to sell, or \$423,353. The Company recognized an impairment loss on investment in associate of \$154,202 upon transfer.

On April 21, 2020, the Company transferred an additional 1,768,545 shares of BaM to a brokerage account for immediate sale. The shares were measured at the lower of their carrying amount and fair value less costs to sell, or \$783,978, and an impairment loss on investment in associate of \$193,504 was recognized upon transfer.

During the year ended March 31, 2020, the Company sold 877,500 BaM shares held for sale for proceeds of \$272,294 and recognized a loss on sale of \$92,439.

During the three and nine months ended December 31, 2020, the Company sold 816,032 BaM shares held for sale for proceeds of \$350,900 and recognized a gain on sale of \$13,283.

The remaining shares classified as held for sale were revalued as of March 31, 2020 to the lower of their carrying amount and fair value less costs to sell, and an additional impairment loss on investment in associate held for sale of \$20,224 was recognized as of the same period ended. The shares held for sale are a part of the Company's cannabis operating segment.

As at December 31, 2020, prior to the change in classification, the remaining 1,093,545 (March 31, 2020 – 141,032) BaM shares classified as held for sale were revalued to the lower of their carrying amount and fair value less costs to sell, or \$530,385 (March 31, 2020 - \$38,396), and a fair value gain of \$300,747 and \$45,627, respectively, for the three and nine months ended December 31, 2020 (fair value loss of \$20,224 for the year ended March 31, 2020).

Change in classification from Investment in Associate and Held for Sale to Marketable Security

As at December 31, 2020, the Company determined that the criteria for significant influence of BaM including control considerations and percentage ownership were no longer met, and both the BaM investment in associate (comprising 18,193,100 BaM shares at a fair value of \$8,823,910) and BaM assets held for sale (comprising 1,093,545 BaM shares at a fair value of \$530,385) were reclassified to marketable securities (see Note 15(c)). The Company recorded a loss on disposition of \$154,913 in the period ended December 31, 2019, representing the difference between the carrying value of the transferred interest and the consideration received in exchange for the transferred interest.

Measurement – Convertible Debenture

The Company measures the convertible debentures at fair value through profit and loss. Through March 31, 2020, fair value was determined for each component of the hybrid instrument by applying a market discount rate to the debt feature and using the Black Scholes model to value the conversion feature. Pursuant to a conversion agreement executed July 1, 2019, the Company agreed to convert all of its unsecured convertible debentures of BaM. in the principal amount of \$1,600,000 at a price of \$0.55 per common share on or before July 1, 2020, to acquire 2,909,091 common shares of BaM. The Company completed the conversion on July 1, 2020.

Upon conversion, the shares represent an increase to the Company's investment in associate. The Company engaged a third-party valuation firm to assess the value of the equity interest of the convertible debentures as of June 30, 2020, the day prior to conversion. Using a market-based approach that takes into account multiples derived from the business and sale of companies similar to BaM, Level 2 inputs, a fair value of \$1,356,500 was assigned to the instrument, resulting in an unrealized loss of \$196,555 during the period then ended. The \$1,356,500 fair value of the converted instrument was deemed the cost basis and was presented as an increase to the Company's carrying value of its investment in associate as at June 30, 2020.

Measurement – Investment in Associate

As of December 31, 2020, and prior to the reclassification as a marketable security (see above), the Company held 18,193,100 shares of BaM, excluding the 1,093,545 shares classified as held for sale. The Company's ownership percentage in BaM's issued and outstanding common stock was 16.8%, or 17.8% including the shares held for sale. As the Company's voting right interest in BaM had fallen below (and was expected to remain below) the 20% threshold for presumed significant influence, and the Company held only one seat on the BaM Board of Directors (while not actively involved in any management of BaM) the Company determined that the significant influence criteria were no longer met, and the BaM shares and investment should no longer be accounted for using equity accounting, rather fair value accounting as a marketable security (see reclassification to marketable security above and Note 15(c)). As a result of this declassification, the Company recognized a \$647,552 loss on investment in associate.

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited) December 31, 2020 and 2019

BaM incorporated in the State of Delaware, United States and is publicly listed in Canada. The reporting periods of BaM differ from that of the Company, such that BaM's most recently published financial statements are typically reported as of the period ended two months prior to that of the Company's current period ended. The Company uses available public financial information to account for the value of the invested entity. Filing of BaM's financial statements for the period ended July 31, 2020, is pending as of the date of authorization of issuance of these unaudited condensed interim consolidated financial statements. Therefore the most recently published financial statements of BaM, are for the period-ended October 31, 2020, and as such, these financial statements were used to determine the proportional loss to be recorded in the Company's financials for the current period. The Company reviewed the significant activity of BaM as communicated through press releases during the period of November 1, 2020 through December 31, 2020 and did not note any material events that could have a material impact on valuation. Management made certain assumptions based on available information, to assess the impact of converting BaM's consolidated statement of operations from US GAAP to IFRS, noting no material likely impacts for the period ending October 31, 2020.

During the three and nine months ended December 31, 2020, the Company recognized a proportional loss on investment of \$48,679 and \$469,774, respectively (\$378,985 and \$2,018,400 for the three and nine months ended December 31, 2019) and a proportional other comprehensive gain of \$239,747 and \$43,330, respectively (\$43,850 and \$132,115 gain for the three and nine months ended December 31, 2019 respectively). The carrying value of the investment at December 31, 2020 was \$9,471,462 (\$10,500,148 at March 31, 2020). Based on BaM's closing stock price of \$0.485 as of December 31, 2020, the 18,193,100 common shares owned by the Company as of that same date had a value of \$8,823,910 - see above for reclassification to marketable security.

Investment in associates - BaM		\$	Number of shares
Opening balance, April 1, 2019:		9,223,456	22,079,788
Additions:			
Warrant Exercise	May 29, 2019	12,921,778	12,793,840
Deletions:	-		
Share issuance - Passport license agreement	October 29, 2019	(2,934,287)	(5,000,000)
Share issuance – ASTOUND service agreement	November 20, 2019	(2,920,498)	(5,000,000)
Share issuance – Rapid cash kiosk agreement	December 14, 2019	(2,904,091)	(5,000,000)
Shares held for sale	February 18, 2020	(577,555)	(1,018,532)
Proportional OCI gain recognized for shares issued/ sold	-	54,323	
Proportional loss recognized – fiscal 2020			
Proportional loss recognized - fiscal 2020		(2,414,953)	
Proportional OCI recognized - fiscal 2020 (net of disposa	ls) ⁽¹⁾	51,975	
Closing balance, March 31, 2020		10,500,148	18,855,096
Additions:			
Conversion of debentures	July 1, 2020	1,356,500	2,909,091
Deletions:	-		
Shares held for sale	April 21, 2020	(977,482)	(1,768,545)
Shares issuance – Passport license true-up	June 13, 2020	(972,401)	(1,802,542)
Proportional OCI gain recognized for shares issued/ sold		(8,859)	
Proportional loss recognized - fiscal 2021			
Proportional loss recognized - fiscal 2021		(469,774)	
Proportional OCI recognized - fiscal 2021 (net of disposa	ls) ⁽¹⁾	43,330	
Subtotal at December 31, 2020		\$9,471,462	18,193,100
Loss of derecognition		(647,552)	-
Balance transferred to marketable security (Note 15(c))		(8,823,910)	(18,193,100)
Closing balance at December 31, 2020		-	-

The Company's investment in BaM can be summarized below:

⁽¹⁾ Proportionate OCI recognized is net of proportional gains/ losses previously recognized in other comprehensive income relating to the Company's reduction in ownership interest, that have been reclassified to the Company's Comprehensive Statement of Loss in the period of disposal.

17. Property, Plant and Equipment

Property, Plant and Equipment held for use and related accumulated depreciation are as follows:

					Transferred to	Foreign	
	March 31,			Impairment	assets held for	currency	December 31
	2020	Additions	Disposals	(loss)/reversal	sale	translation	2020
Cost	\$	\$	\$	\$	\$	\$	\$
Land	3,944,073	-	-	-	(3,944,073)	-	-
Computer equipment	66,313	24,679	(16,380)	-	-	(5,369)	69,243
Furniture & fixtures	109,238	-	-	-	-	(11,203)	98,035
Leasehold improvements	31,528	2,011	-	-	-	(3,233)	30,306
Production equipment	200,370	-	-	-	-	-	200,370
Construction in progress	686,278	1,408,069	-	-	(2,033,562)	(60,785)	-
	5,037,800	1,434,759	(16,380)	-	(5,977,635)	(80,590)	397,954
Accumulated depreciation							
Computer equipment	18,060	19,539	(4,443)	-	-	(1,209)	31,947
Furniture & fixtures	25,736	14,883	-	-	-	(2,640)	37,979
Leasehold improvements	5,340	4,838	-	-	-	(548)	9,630
Production equipment	57,641	50,092	-	-	-	-	107,733
	106,777	89,352	(4,443)	-	-	(4,397)	187,289
Net book value							
Land	3,944,073	-	-	-	(3,944,073)	-	-
Computer equipment	48,253	5,140	(11,937)	-	-	(4,160)	37,296
Furniture & fixtures	83,502	(14,883)	-	-	-	(8,563)	60,056
Leasehold improvements	26,188	(2,827)	-	-	-	(2,685)	20,676
Production equipment	142,729	(50,092)	-	-	-	-	92,637
Construction in progress	686,278	1,408,069	-	-	(2,033,562)	(60,785)	-
	4,931,023	1,345,407	(11,937)	-	(5,977,635)	(76,193)	210,665

Depreciation expense for the three and nine months ended December 31, 2020 amounted to \$29,279 and \$88,419 respectively, which included \$1,212 and \$2,635 recognized to cost of goods sold for the three and nine months then ended, and \$28,067 and \$85,784 to operating expenses in the condensed interim consolidated statements of comprehensive loss for the three and nine months then ended (three and nine months ended December 31, 2019 – \$27,262 and \$67,752 respectively, all of which was recognized to operating expenses during the periods).

Property, Plant and Equipment held for sale are as follows (Note 7 and 10):

				T	ransferred to	Foreign	
	March 31,			Impairment as	sets held for	currency	December 31,
	2020	Additions	Disposals	loss	sale	translation	2020
Cost	\$	\$	\$	\$	\$	\$	\$
Land held for sale	2,977,532	-	-	(2,250,241)	6,020,850	(305,371)	6,442,770

During the period ended September 30, 2020, the Company reclassified its North Las Vegas land, and land improvements made to the North Las Vegas land that were previously carried in Construction in Progress, to land held for sale (Note 10).

18. Goodwill and Intangible Assets

Identifiable intangible assets, and the related reconciliation of beginning and ending balances, are as follows:

			Additions:					
			acquired in				December	
		March 31,	business				31,	Remaining
Intangible	Notes	2020	combination .	Amortization	Disposals	Impairment	2020	useful life
Definite life intangible assets:		\$	\$	\$	\$	\$	\$	Years
Software		1,810,135	-	-	-	(1,810,135)	-	
Brands	9	3,472,787	-	(284,972)	-	-	3,187,815	8.4
License – IP	12	5,454,544	-	(169,697)	-	(5,284,847)	-	
Relationships	11, 13	-	105,345	(6,271)	(99,074)	-	-	
Indefinite life intangible assets:								
Licenses and permits	9	4,038,000	-	-	-	-	4,038,000	
Total intangible assets held for use, net		14,775,466	105,345	(460,940)	(99,074)	(7,094,982)	7,225,815	
Intangible assets held for sale:								
Brands	8	382,000	-	-	-	(382,000)	-	
Total intangible assets held for sale		382,000	-	-	-	(382,000)	-	

Amortization expense for the three and nine months ended December 31, 2020 amounted to \$231,355 and \$460,940 respectively, which included \$136,364 and \$169,697 recognized to cost of goods sold for the three and nine months then ended, and \$94,991 and \$291,243 to operating expenses in the condensed interim consolidated statements of comprehensive loss for the three and nine months then ended (three and nine months ended December 31, 2019 – \$94,990 and \$231,859 respectively, all of which was recognized to operating expenses during the period). During the nine months ended December 31, 2020, the Company recognized an impairment loss of \$1,810,135 on the Rthm software and \$5,284,847 on the Passport license which management deemed to not have ongoing value.

The following is a continuity schedule of the Company's goodwill, comprised of the goodwill arising in the Company's acquisitions of Rthm and Paytron, both belonging to the Company's technology operating segment:

		March 31,				December 31,
Goodwill	Notes	2020	Additions	Disposals	Impairment	2020
Fiscal 2020 acquisitions:		\$	\$	\$	\$	\$
Rthm goodwill						
Acquisition of Rthm		1,644,843	-	-	-	1,644,843
(Accumulated impairment – Rthm)		(1,055,000)	-	-	(589,843)	(1,644,843)
Rthm goodwill, net		589,843	-	-	(589,843)	-
Fiscal 2021 acquisitions:						
Paytron goodwill						
Acquisition of Paytron	11, 13	-	114,541	(114,541)	-	-
(Accumulated impairment – Paytron)		-	-	-	-	-
Paytron goodwill, net		-	114,541	(114,541)	-	-
Total goodwill		589,843	114,541	(114,541)	(589,843)	-

During the nine months ended December 31, 2020, the Company recognized an impairment loss of \$589,843 in connection with the goodwill acquired in the Rthm acquisition as in management's estimation the carrying amount will no longer be recoverable.

19. Share Capital

(a) Authorized

Unlimited number of common voting shares without par value; and Unlimited number of preferred non-voting shares without par value.

(b) Issued and outstanding

As of December 31, 2020, there were 176,758,451 issued and outstanding common shares. As of March 31, 2020, there were 169,943,997 issued and outstanding common shares.

- (i) On May 21, 2019, the Company entered into an asset purchase agreement with Green Therapeutics, LLC to acquire its Tsunami, Provisions, and GT Flowers cannabis brands, certain operating assets, intellectual property and the right to assume, and complete the construction of a cultivation and production facility. The Company issued 7,831,855 shares at a price of \$1.10 per share for a total of \$8,615,041, with a fair value of \$7,322,241 as described in Note 9, upon the signing of a definitive agreement. Upon achievement of certain milestones, the Company will issue an additional USD \$1,600,000 in the Company's common stock. A finder's fee of 109,090 shares of the Company, at a price of \$1.10 per share for a total of \$119,999 and with a fair value of \$101,991, was issued in conjunction with this transaction (Note 9).
- On May 21, 2019, the Company acquired from Meridian Companies LLC an 8.9-acre parcel of land in North Las Vegas. The Company issued 3,585,521 shares at a price of \$1.10 per share for a total of \$3,944,073 of its common stock (Note 10).
- (iii) On October 29, 2019, the Company entered into a ten-year License, Development and Services Agreement with Passport Technology Canada Ltd to acquire an exclusive license to Passport's proprietary platform and technology for use in cannabis dispensaries. As consideration, the Company issued 1,829,219 shares at a price of \$0.58 per share for a total of \$1,058,626 of its common stock (Note 12).
- (iv) On April 1, 2020, the Company acquired 100% of the equity interest of Paytron, LLC, a merchant service provider. The Company issued 949,926 shares at a price of \$0.18 per share for a total fair value of \$170,717 (Note 11).
- (v) On September 3, 2020, the Company issued 4,250,000 shares to its former CEO and Director in connection with his resignation from the Company and the formal termination and full and final settlement of the Company's proposed acquisition of Passport Technology, Inc. (Note 13). The shares were issued at a price of \$0.14 per share for a total fair value of \$595,000.
- (vi) The Company issued an aggregate of nil common shares on the exercise of nil warrants for gross proceeds of nil for the nine months ended December 31, 2020 (9,999,838 common shares issued on the exercise of 9,999,838 warrants for gross proceeds of \$2,499,960 for the nine months ended December 31, 2019).

- (vii) The Company issued an aggregate of nil common shares on the exercise of nil stock options, net of shares withheld for tax, for gross proceeds of nil for the nine months ended December 31, 2020 (726,353 common shares on exercise of 900,000 stock options, net of shares withheld for tax, for gross proceeds of \$180,000 for the nine months ended December 31, 2019).
- (viii) The Company issued an aggregate of 2,148,509 common shares, net of shares withheld for tax, upon vesting of 2,101,882 RSUs for the nine months ended December 31, 2020 (614,167 common shares, net of shares withheld for tax, upon vesting of 225,000 RSUs for the nine months ended December 31, 2019).
- (c) Treasury shares

Pursuant to the terms of the Modification, Settlement, Assignment and Consent Agreement entered into by the Company, Mr. Natural Productions, Inc. and Robert Luciano (collectively, the "Natural Parties") and a third party assignee, on April 30, 2020, the Natural Parties returned to the Company 533,981 common shares of the Company. The fair value of the shares returned is \$0.19 per share, for a total of \$101,456 based on the market price of the Company shares at close on the day prior to execution of the agreement. The amount is reflected as treasury shares in the consolidated statement of financial position (Note 8).

(d) Share purchase warrants

Each whole warrant entitles the holder to purchase one common share of the Company. The balance of warrants at December 31, 2020 are held by ACB in connection with the Spin-out Transaction (Note 5). A summary of the status of the warrants outstanding follows:

		Weighted average exercise
	Warrants	price
	#	\$
Balance March 31 2020	30,929,562	0.85
Forfeited	(8,300,811)	0.39
Balance December 31, 2020	22,628,751	0.20

The following table summarizes the warrants that remain outstanding as at December 31, 2020:

Exercise price	Warrants	Expiry date
\$	#	
0.20	22,628,751	September 19,2028
	22,628,751	

(e) Stock options

On June 15, 2018, the Board adopted a Share Option Plan which provides that the Board may from time to time, in its discretion, and in accordance with exchange requirements, grant to directors, officers, employees, and consultants, non-transferable stock options to purchase common shares of the Company. Each option granted under the Share Option Plan carries a five-year life and vests over a term of three years such that one-third vests in year one, one-third vests in year two and the final third vests in year three, unless otherwise designated below. At the AGM held on November 17, 2020 the shareholders of the Company did not approve the ratification of the Share Option Plan. As a result, the options outstanding under such plan continue to exist, but no new options are able to be granted under such plan. Effective on December 1, 2020 the Board adopted a new Share Option Plan that is essentially identical to the former plan but with a reduced cap on the maximum number of options that can be granted (reduced from 15% of the issued and outstanding shares to 10% of the issued and outstanding shares). Options have been granted under the new Share Option Plan, but all such grants are conditional on receipt of shareholder approval of the new Share Option Plan and the Company's next annual meeting of shareholders.

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited) December 31, 2020 and 2019

The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. The following weighted average inputs were used in determining the fair value of options granted during the nine-months ended December 31, 2020 and December 31, 2019:

	Nine months ended D	ecember 31,
	2020	2019
Fair value at grant date	\$0.08	\$0.49
Share price at grant date	\$0.14	\$0.87
Exercise price	\$0.14	\$0.87
Expected volatility	91%	80%
Expected option life	3.7 years	3.5 years
Expected dividends	- · · · · ·	-
Risk free rate	0.36%	1.51%

As the Company's trading history is less than the expected life of the options granted, the Company uses an expected volatility estimate based on an average of the Company's historical volatility and that of comparable companies operating in the cannabis industry. The expected option life represents the period of time that the options granted are expected to be outstanding. Expected dividend yield is based on the fact that the Company has not paid cash dividends and does not expect to do so in the foreseeable future. The risk-free interest rate is determined by reference to the Canada government bonds with a remaining term equal to the expected life of the options.

A summary of the status of stock options outstanding follows:

	Stock options	Weighted average exercise price
	#	\$
Balance March 31, 2020	18,964,930	0.62
Granted	12,489,467	0.15
Expired	(71,350)	0.51
Forfeited	(25,344,455)	0.46
Balance December 31, 2020	6,038,592	0.34

The following table summarizes the stock options that remain outstanding as at December 31, 2020:

Weighted average exercise price	Outstanding options	Expiry date	Options exercisable
\$	#		#
0.40	100,000	August 13, 2023	66,666
0.20	120,000	September 11, 2023	79,999
1.62	40,000	November 13, 2023	26,666
0.98	248,000	April 13, 2024	82,666
1.05	600,000	June 3, 2024	200,000
0.84	20,000	August 19, 2024	6,666
0.69	56,000	September 30, 2024	18,666
0.65	229,950	October 2, 2024	76,650
0.18	666,142	March 11,2025	-
0.18	73,500	May 11, 2025	-
0.28	35,000	June 8, 2025	-
0.18	3,850,000	December 7, 2025	-
	6,038,592		557,979

During the three and nine months ended December 31, 2020, the Company recorded a net reversal of share-based payment expense of \$894,400 and \$553,180 respectively, in connection with the vesting, expiration and forfeiture of stock options, (three and nine months ended December 31, 2019 – a share-based payment expense of \$748,964 and \$1,506,809 respectively). In addition to the amounts recognized above, share-based payment expense was recognized within consulting fees of \$nil and \$4,075 for the three and nine months ended December 31, 2020 respectively, in connection with stock options, (\$nil in the comparative periods ended December 31, 2019).

(f) Restricted Share Units

On November 13, 2018, the Board adopted a Restricted Share Unit Plan which provides that the Board may from time to time, in its discretion, and in accordance with exchange requirements, grant to directors, officers, employees, and consultants, non-transferable restricted share units of the Company ("RSU"). Each RSU granted under the Restricted Share Unit Plan vests over a term of three years such that one-third vests in year one, one-third vests in year two and the final third vests in year three. RSUs are granted based on the closing price on the date prior to the grant date. At the AGM held on November 17, 2020 the shareholders of the Company did not approve the ratification of the Restricted Share Unit Plan. As a result, the RSUs outstanding under such plan continue to exist but no new RSUs are able to be granted under such plan. Effective on December 1, 2020 the Board adopted a new Restricted Share Unit Plan that is essentially identical to the former plan but with a reduced cap on the maximum number of options that can be granted (reduced from 15% of the issued and outstanding shares to 10% of the issued and outstanding shares). Any RSUs granted under the new plan prior to receipt of shareholder approval are conditional grants that are subject to the shareholder approval of the new plan.

The following tables represent the Company's Restricted Share Units during the period:

	RSU's granted	Weighted average issue price
	#	\$
Non-vested balance March 31, 2020	5,378,441	0.75
Granted	342,796	0.14
Vested	(3,276,022)	0.83
Forfeited	(1,934,693)	0.59
Non-vested balance December 31, 2020	510,522	0.48

RSU's Outstanding Vesting date⁽¹⁾ Issue price \$ # November 13, 2021 1.62 6,667 0.9821.333 April 13, 2022 1.05 100,000 June 3, 2022 0.84 3,333 August 19, 2022 0.68 16,000 September 29, 2022 0.60 61,200 October 2, 2022 0.18 255,489 March 11, 2023 31,500 May 11, 2023 0.18 0.28 15,000 June 8, 2023 510,522

The following table summarized the RSUs that remain outstanding as at December 31, 2020:

⁽¹⁾ RSU's vest ratably over a period of three years. Vesting dates listed above, represent the end of the three-year term. At the end of each annual period from date of grant, one-third of the units granted, will vest.

During the three and nine months ended December 31, 2020, the Company recorded a net reversal of share-based payment expense of \$368,726, and a net share-based payment expense of \$944,687 respectively in connection with the vesting and forfeiture of RSU's, (three and nine months ended December 31, 2019 – a share-based payment expense of \$638,809 and \$1,747,021 respectively). In addition to the amounts recognized above, share-based payment expense was recognized within consulting fees of \$nil and \$4,666 for the three and nine months ended December 31, 2020 respectively, in connection with RSU's granted, (\$nil in the comparative periods ended December 31, 2019).

20. Selling, general and administrative expense

Selling, general and administrative expenses consist of the following:

	For the three months ended		For the nine n	For the nine months ended	
	December 31,	December 31,	December 31,	December 31,	
	2020	2019	2020	2019	
	\$	\$	\$	\$	
Selling, general and administrative expenses:					
Consulting fees	98,253	182,710	132,613	426,030	
Advertising and promotion	115,687	73,885	261,157	282,577	
Office and administration	55,365	54,243	148,394	132,380	
Insurance	167,243	167,565	502,546	387,504	
Regulatory and transfer agent fees	70,124	116,980	120,825	192,482	
Travel and entertainment	6,034	74,173	18,728	255,006	
Professional fees	2,025,836	138,177	2,853,394	1,330,210	
Research and development	19,419	-	100,080	-	
Total selling, general and administrative expenses	2,557,961	807,733	4,137,737	3,006,189	

21. Segmented Information

During the year ended March 31, 2020, the Company revised the composition of its reportable operating segments such that the new segments reflect the information used by the Company's CODM in making decisions about resources to be allocated to the segments and about segment performance. Prior period comparative information has been adjusted to reflect these changes. Additionally, and in connection with the launch of operations of the Company's wholly owned subsidiary Cocoon Technology during the nine months ended December 31, 2020, the Company presents disaggregated revenue based on the relevant operating segment, and the timing of transfer of goods or services to the Company's customers in accordance with the Company's revenue recognition policy:

	Cannabis	Technology	Total
	\$	\$	\$
As at December 31, 2020			
Non-current assets	21,514,246	3,066,954	24,581,200
Non-current liabilities	(1,709,513)	-	(1,709,513)
As at March 31, 2020			
Non-current assets	27,602,827	12,381,914	39,984,741
Non-current liabilities	(2,058,843)	-	(2,058,843)
Nine months ended December 31, 2020			
Revenue			
Goods and services transferred at a point in time	-	71,510	71,510
Goods and services transferred over time	173,341	13,129	186,470
Loss from operations	(9,546,211)	(803,060)	(10,349,271)
Net loss	(26,293,709)	(2,256,285)	(28,549,994)
Nine months ended December 31, 2019			
Revenue			
Goods and services transferred at a point in time	-	-	-
Goods and services transferred over time	155,065	14,069	169,134
Loss from operations	(10,590,596)	(297,989)	(10,888,585)
Net loss	(12,483,501)	(301,160)	(12,784,661)

One-time losses incurred during the three and nine months ended December 31, 2020, include the loss on true-up provision of \$1,615,835 (Note 14(a)) and the loss on settlement of \$1,025,477 (Note 13), that are allocated approximately equally to the Cannabis and Technology operating segments.

22. Related Party Transactions

The Company incurred the following transactions with related parties during the three and nine months ended December 31, 2020 and 2019:

	For the three r	For the three months ended		For the nine months ended	
	December 31,	December 31,	December 31,	December 31,	
	2020	2019	2020	2019	
	\$	\$	\$	\$	
Settlements (Note 13)	-	-	1,027,477	-	
Wages and benefits ⁽¹⁾	200,397	488,626	765,260	1,435,301	
Directors' fees ⁽²⁾	(576,621)	458,056	302,850	1,619,027	
Share-based compensation to related parties (3)	(392,875)	208,161	260,307	1,928,485	

⁽¹⁾ The Company's key management personnel have the authority and responsibility for planning, directing and controlling the activities of the Company and consist of the Company's executive management team.

⁽²⁾ The Company's directors' fees include one-time compensation paid to the Special Committee members in August 2020, compensation paid the Executive Chairman of the Board, and share-based compensation for the directors, during the periods presented.

⁽³⁾ The Company's related parties included for share-based compensation are the executive management team during the periods presented.

The following related party amounts were included in related party advances-payable, provisions and in receivables as at December 31, 2020 and March 31, 2020:

	December 31,	March 31,
	2020	2020
	\$	\$
Other receivable ⁽¹⁾	9,470	76,460
Due from officers	- · · · · ·	28,374
Provisions (Note 12)	-	855,423

⁽¹⁾ The amount is unsecured and includes advances of the employee portion of payroll taxes on RSU's exercised. The payroll taxes on the RSU's exercised have no fixed repayment terms.

23. Financial Instruments and Risk Management

(a) Fair value of financial instruments

The Company's financial instruments consist of cash, accounts receivable, annuity receivable, marketable securities, accounts payable and accrued liabilities, provisions, contingent consideration payable, and advances payable. Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the significance of the inputs to fair value measurements. The three Levels of hierarchy are:

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; and

Level 3 – Inputs for the asset or liability that are not based on observable market data.

The carrying values of cash, accounts receivable, and accounts payable and accrued liabilities approximate their fair values as at December 31, 2020 due to the relatively short-term maturity. The carrying value of the Company's annuity receivable – SubTerra approximates its fair value (Note 6). The Company's investments in marketable securities of Quality Green is in a private company where relevant observable inputs are not available and is classified as Level 3 (Note 15a). The Company's investment in marketable securities of BaM has a quoted market price in the public market (Note 15c) and is classified as Level 1. The Company's provision payable is calculated based on the agreement with Astound and is classified as Level 3 (Note 14a). The fair value of contingent consideration payable is classified as Level 3 and is based upon management's best estimate of the probability and timing of achieving the milestones to which the obligation is tied to (Note 9).

There have been no transfers between fair value Levels during the period.

Fair value Amortized Total through profit cost or loss \$ \$ \$ 7.585.221 Cash 7,585,221 -Accounts receivable 129,256 129,256 Annuity receivable - SubTerra 739,068 739,068 Marketable securities - Quality Green 500.678 500.678 -Marketable securities - BaM 9,354,295 9,354,295 Accounts payable and accrued liabilities 4,684,384 4,684,384 Provisions 4,615,835 4,615,835 Contingent consideration payable 1,299,937 1,299,937

The following table summarizes the Company's financial instruments as at December 31, 2020:

(b) Financial instruments risk

(i) Credit risk

Credit risk is the risk of a potential loss to the Company if a customer or third party to a financial instrument fails to meet its contractual obligations. The Company is moderately exposed to credit risk from its accounts receivables and its annuity receivable (Notes 4 and 6). The risk exposure is limited to their carrying amounts at the statement of financial position date. Credit risk arises from the possibility that principal and/or interest due may become uncollectible. The Company mitigates this risk to the extent possible, by managing and monitoring the underlying business relationships.

For financial assets carried at amortized cost, the Company recognizes loss allowances for expected credit losses ("ECLs"), where applicable. ECLs are a probability-weighted estimate of credit losses. The Company applies a three-stage approach to measure ECLs. The Company measures loss allowance at an amount equal to twelve months of expected losses if the credit risk at the reporting date has not increased significantly since initial recognition (Stage 1) and at an amount equal to lifetime expected losses if there is a significant increase in credit risk since origination (Stage 2) and at an amount equal to lifetime expected losses which are credit impaired (Stage 3).

The Company considers a significant increase in credit risk to have occurred if contractual payments are more than 30 days past due and considers the financial assets carried at amortized cost to be in default if they are 90 days past due. A significant increase in credit risk or default may have also occurred if there are other qualitative factors (including forward looking information) to consider; such as borrower specific information (i.e. change in credit assessment). Such factors include consideration relating to whether the counterparty is experiencing significant financial difficulty, there is a breach of contract, concessions are granted to the counterparty that would not normally be granted, or it is probable the counterparty will enter into bankruptcy or a financial reorganization. Significant increases in credit risk are assessed based on changes in probability of default of a financial asset subsequent to initial recognition. The Company uses past due information to determine whether credit risk has increase significantly since initial recognition. Financial assets are considered to have experienced a significant increase in credit risk and are reclassified to Stage 2 if a contractual payment is more than 30 days past due as at the reporting date.

The Company defines default as the earlier of when a contractual payment is more than 90 days past due or when a loan becomes insolvent as a result of customer bankruptcy. Financial assets that have experienced a default event are considered to be credit impaired and are reclassified as Stage 3 loans.

The Company measures ECL by considering the risk of default over the contract period and incorporates forwardlooking information into its measurement. ECLs are measured as the difference in the present value of the contractual cash flows that are due to the Company under the contract, and the cash flows that the Company expects to receive. The Company assesses all information available, including past due status and forward looking macro-economic factors in the measurement of the ECLs associated with its assets carried at amortized cost.

The maximum period considered when estimating ECLs is the maximum contractual period over which the Company is exposed to credit risk. Based on the payment history of the Company's annuity receivable, as well as the nature of the Company's remaining receivables measured at amortized cost, there are currently no ECLs recognized with respect to such receivables as at December 31, 2020.

(ii) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations associated with financial liabilities. The Company manages liquidity risk through the management of its capital structure. The Company's approach to managing liquidity is to ensure that it will have sufficient liquidity to settle obligations and liabilities when due.

As at December 31, 2020, the Company has the following contractual obligations:

	Total	<1 year	1 - 3 years	1-5 years
	\$	\$	\$	\$
Accounts payable and accrued liabilities	4,684,384	4,684,384	-	-
Provisions (Note 14(a))	4,615,835	4,615,835	-	-
Contingent consideration payable ⁽¹⁾	1,229,937	-	1,229,937	-
Lease liability	564,422	154,846	371,278	38,298

⁽¹⁾ Contingent consideration payable is outlined in Note 9 of the Company's unaudited condensed interim consolidated financial statements for the three and nine months ended December 31, 2020. The above reflects management's forecasted timing of achievement of the related milestones.

(iii) Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market related factors, such as foreign exchange rates and interest rates. The objective of market risk management is to manage and control market risk exposures within acceptable parameters.

Currency risk

The operating results and financial position of the Company are reported in Canadian dollars. As the Company operates in an international environment, some of the Company's financial instruments and transactions are denominated in currencies other than the Canadian dollar. The results of the Company's operations are subject to currency transaction and translation risks.

At December 31, 2020, the Company held cash in Canadian and U.S. dollars. The Company's main risk is associated with fluctuations in the U.S. dollar. Assets and liabilities are translated based on the foreign currency translation policy. The Company has determined that a 10% increase or decrease in the U.S. dollar against the Canadian dollar on financial assets and liabilities would result in an increase or decrease of approximately \$297,846 (nine months ended December 31, 2019 - \$479,034) to net and to comprehensive loss for the nine months ended December 31, 2020.

At December 31, 2020, the Company has not entered into any agreements or purchased any instruments to hedge possible currency risks at this time.

• Price risk

Price risk is the risk of unfavorable changes in the fair values of equity instruments or equity-linked derivatives as a result of changes in the value of individual shares. Equity price risk exposure arises from the Company's investments in Canada and U.S. cannabis related assets, and from derivatives linked with such. The Company manages this risk by routinely monitoring and assessing the performance and outlook of its investments. The Company has determined that a 10% increase or decrease in the fair value of these financial assets would result in an increase or decrease of approximately \$985,497 to net and comprehensive loss for the nine months ended December 31, 2020.

(iv) Concentration risk

Concentration risk indicates the relative sensitivity of the Company's performance to developments affecting a particular industry or geographical location. Concentrations of risk arise when a number of financial instruments or contracts are entered into with the same counterparty, or where a number of counterparties are engaged in similar business activities, or activities in the same geographical region, or have similar economic features that would cause their ability to meet contractual obligations to be similarly affected by changes in economic, political or other conditions. Concentrations of liquidity risk may arise from reliance on a particular market in which to realize liquid assets. Concentrations of foreign exchange risk may arise if the Company has a significant net open position in a single foreign currency.

The Company's investments in predominately U.S. cannabis assets expose the Company to a certain amount of concentration risk.

24. Capital Management

The Company's objectives when managing capital are to ensure that there are adequate capital resources to safeguard the Company's ability to continue as a going concern and maintain adequate levels of funding to support its ongoing operations and development such that it can continue to provide returns to shareholders and benefits for other stakeholders.

The capital structure of the Company consists of items included in shareholders' equity, net of cash. The Company manages its capital structure, and makes adjustments to it, in light of changes in economic conditions and the risk characteristics of the Company's underlying assets. The Company plans to use existing funds, as well as funds from the future sale of products and services to fund operations and expansion activities. The Company made no changes to its capital structure or management of its capital structure during the nine months ended December 31, 2020.

As at December 31, 2020, the Company is not subject to externally imposed capital requirements.

25. Commitments and Contingencies

Lease Commitment

The Company's lease commitment consists of its lease for office space. The following table summarizes the Company's undiscounted lease payments as of December 31, 2020:

Commitment period	\$
Less than 1 year	214,286
Greater than 1 and less than 5 years	468,347
Greater than 5 years	-
Total Commitment	682,633

Notes to the Condensed Interim Consolidated Financial Statements (Unaudited) December 31, 2020 and 2019

The following table provides a reconciliation of the Company's lease liability for the nine months ended December 31, 2020:

	\$
Opening Balance, April 1, 2020	751,913
Lease payments (Apr – Dec 2020)	(150,045)
Amortization of discount	57,723
Foreign translation adjustment	(95,169)
Lease liability at December 31, 2020	564,422

The total interest expense on lease liabilities for the three and nine months ended December 31, 2020 was \$17,802 and \$57,723 respectively (\$22,770 and \$71,179 for the three and nine months ended December 31, 2019). Total cash outflows for the three and nine months ended December 31, 2020 were \$36,153 and \$150,045 respectively (\$55,609 and \$185,363 for the three and nine months ended December 31, 2019).

Key movements relating to the right-of-use asset balances are presented below:

Carrying value of right-of-use assets	\$
Carrying amount, April 1, 2020	744,502
Addition to leased assets	-
Depreciation expense	(129,456)
Foreign currency translation	(95,755)
Carrying amount, December 31, 2020	519,291

Legal

On June 29, 2020 the Company was served with a lawsuit naming the Company that has been filed, under seal, in Clark County, Nevada by Meridian Companies, LLC and Green Therapeutics, LLC. The lawsuit alleges, among other things, breach of contract by the Company with respect to certain obligations outlined in the Company's asset purchase agreement with Green Therapeutics entered into on May 21, 2019. On January 4, 2021 the parties announced a resolution to their dispute (Note 26).

On November 2, 2020 the Company received a derivative lawsuit from a shareholder. The new management believes the matters have been addressed with the changes in the board and management as referenced in Note 1.

On January 28, 2021 a former CEO and Director filed a defamation suit against the Company. The Company feels this suit is without merit and is working to resolve the matter.

On February 1, 2021 Rapid Cash served the Company with notice of termination of the agreement due to material breech and representation. On February 12, 2021 the Company responded, disputing those claims and rejected the unilateral termination of the agreement. (Note 14b)

On February 1, 2021, Astound served the Company notice to make the true-up payment. The Company is in the process of negotiating a settlement with Astound. (Note 14a)

26. Subsequent Events

On December 30, 2020, the Company announced the appointment of Jon Paul as its new Chief Financial Officer effective January 1, 2021.

On January 4, 2021, the Company entered into a non-binding term sheet with GT and the holders of the issued and outstanding membership interests of GT setting forth the terms of a proposed transaction pursuant to which ACI will purchase 100% of the issued and outstanding membership interests in GT. Prior to completing the acquisition, the parties have agreed to settle a previously announced legal dispute regarding the original May 2019 transaction whereby the Company had acquired certain non-operational GT assets.

On January 5, 2021, the Company and 2750176 Ontario Inc. ("ALPS") announced that they, along with the holders of the outstanding shares of ALPS, entered into a non-binding term sheet setting forth the terms on which the Company is to acquire 51% of the issued and outstanding shares of ALPS, with an option to purchase the remaining 49%. As a condition to the completion of the proposed transaction, Terry Booth, currently a principal of ALPS, will become CEO of the Company at closing, taking over from Dr. Duke Fu, who has been serving as Interim CEO since November 17, 2020. At the time of closing the ALPS acquisition, Dr. Fu will take on the role of COO of the Company. On February 24, 2021, the Company announced it has reached a definitive agreement with ALPS and its shareholders on this acquisition and expects to close the acquisition in early March 2021.

On January 5, 2021, GT has reached an agreement on the sale of land in North Las Vegas. In accordance with the settlement arrangement with Meridian, if the transaction is completed, AUSA will receive approximately USD \$1.95 million upon closing, along with the return of 3,585,521 shares of the Company being returned by Meridian, subject to the satisfaction of the applicable closing conditions. The transaction is scheduled to close in March 2021.